Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Further information: Congenital adrenal hyperplasia

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Other names	21-OH CAH
CT scan shows enlarged adrenals with masses consistent with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (image credit: NICHD/A. Mallappa, D. Merke)
Specialty	Endocrinology
Symptoms	Androgen excess and corticosteroid deficiencies
Frequency	1:18,000 to 1:14,000 (classical forms); 1:1000 to 1:50 (nonclassical forms)

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) is a genetic disorder characterized by impaired production of cortisol in the adrenal glands. ^[1]

It is classified as an inherited metabolic disorder. CAH is an autosomal recessive condition since it results from inheriting two copies of the faulty CYP21A2 gene responsible for 21-hydroxylase enzyme deficiency. The most common forms of CAH are: classical form, usually diagnosed at birth, and nonclassical, late onset form, typically diagnosed during childhood or adolescence, although it can also be identified in adulthood when seeking medical help for fertility concerns or other related issues, such as PCOS or menstrual irregularities. ^[1] Carriers for the alleles of the nonclassical forms may have no syptoms, such form of CAH is sometimes called cryptic form. ^{[2] [3]} Congenital adrenal hyperplasia due to 21-hydroxylase deficiency in all its forms accounts for over 95% of diagnosed cases of all types of congenital adrenal hyperplasia. ^[4] Unless another specific enzyme is mentioned, CAH in most contexts refers to 21-hydroxylase deficiency, and different mutations related to enzyme impairment have been mapped on protein structures of the enzyme. ^[5] It is one of the most common autosomal recessive genetic diseases in humans. ^{[6] [7] [8]}

Due to loss of 21-hydroxylase function, patients are unable to efficiently synthesize cortisol. As a result, ACTH levels increase, leading to adrenocortical hyperplasia and overproduction of cortisol precursors, which are used in the synthesis of sex steroids, which can lead to signs of androgen excess, including ambiguous genitalia in newborn girls and rapid postnatal growth in both sexes. ^[1] In severe cases of CAH in females, surgical reconstruction may be considered to create more female-appearing external genitalia. However, there is ongoing debate regarding timing and necessity of surgery. The way CAH affects the organism is complicated, and not everyone who has it will show signs or have symptoms. ^[4] Individuals with CAH may face challenges related to growth impairment during childhood and fertility issues during adulthood. Psychosocial aspects such as gender identity development and mental health should also be taken into consideration when managing individuals with CAH. ^[1] Overall prognosis for individuals with appropriate medical care is good; however, lifelong management under specialized care is required to ensure optimal outcomes. ^[1]

Treatment for CAH involves hormone replacement therapy to provide adequate levels of glucocorticoids and mineralocorticoids. Regular monitoring is necessary to optimize hormone balance and minimize potential complications associated with long-term glucocorticoid exposure. ^[1]

Presentation

CAH can occur in various forms. The clinical presentation of each form is different and depends to a large extent on the kind of the underlying 21-hydroxylase enzyme defect. ^[9] Classical forms appear in infancy, and nonclassical forms appear in late childhood. The presentation in patients with classical CAH can be further subdivided into two forms: salt-wasting and simple-virilizing, depending on whether mineralocorticoid deficiency presents or absents, respectively. ^{[1] [10] [11]} This subtyping is often not clinically meaningful, because all patients with classical form lose salt to some degree, and clinical presentations may overlap. ^[12]

Severe, early onset 21-hydroxylase deficient CAH

The two most serious neonatal consequences of 21-hydroxylase deficiency are the following: life-threatening salt-wasting crises in the first month of life (for male and female infants alike) and severe virilization of female infants which can cause genital ambiguity. ^{[13] [14]} The subdivision of the early onset CAH into salt-wasting and simple-virilizing forms, which is based on the capacity of the adrenal to produce small amounts of aldosterone in the simple-virilizing form, is often not clinically meaningful, because clinical presentations overlap and all patients lose salt to some degree. ^[12]

Salt-wasting crises in infancy

Excessive levels of androgens of adrenal origin ^{[15] [16] [17] [18]} have little effect on the genitals of male infants with classical CAH. ^[15] If a male infant with CAH goes undetected during newborn screening, he will exhibit normal health and physical appearance upon examination, leading to his timely discharge from the hospital. ^{[19] [20] [21] [22]}

Aldosterone insufficiency in salt-wasting CAH results in significant loss of sodium in the urine. Urinary sodium concentrations may exceed 50 mEq/L. Due to the loss of salt at that rate, the infant is unable to maintain proper blood volume and begins to suffer from dehydration due to hyponatremia by the end of the first week of life. Potassium and acid excretion are also impaired when mineralocorticoid activity is deficient, and hyperkalemia and metabolic acidosis gradually develop. When there's not enough cortisol in the body due to the classical CAH, it becomes harder to have proper blood circulation. Inadequate circulation can cause problems like spitting and difficulty gaining weight in babies. Furthermore, infants with salt-wasting CAH may experience even worse symptoms like vomiting, extreme dehydration, and their circulation can suddenly fail (which is called circulatory shock) within two or three weeks after birth. ^[19]

Upon admission to a medical facility, the infant between the ages of 1 and 3 weeks will exhibit signs of both underweight and dehydration. ^[19] The blood pressure may be abnormally low. Basic laboratory analyses will indicate low levels of sodium (hyponatremia), typically falling between 105 and 125 mEq/L Na⁺ in serum samples. These infants may also experience severe hyperkalemia with potassium (K⁺) levels exceeding 10 mEq/L, along with significant metabolic acidosis. Hypoglycemia (low blood sugar) might also be observed. This collection of manifestations is referred to as a "salt-wasting crisis" which poses an imminent risk of fatal consequences if left untreated. ^[23]

Despite the severity of this condition, affected infants respond swiftly to treatment involving hydrocortisone administration along with intravenous infusion of saline solution and dextrose supplementation. Consequently, normal blood volume is promptly restored alongside stabilization of blood pressure and restoration of appropriate body sodium levels, leading to reversal of hyperkalemia. With prompt and apt management measures in place, most infants are no longer at risk within a span of approximately 24 hours. ^{[24] [25] [26]}

Virilization of female infants

The androgen backdoor pathway (red arrows) roundabout testosterone embedded in within conventional androgen synthesis that lead to 5α-dihydrotestosterone through testosterone

CAH is a genetic disorder characterized by impaired production of cortisol in the adrenal glands. ^{[1] [4]}

Production of cortisol begins at week 8 of fetal life. ^{[30] [31] [32]}

The 21-hydroxylase enzyme is essential in conversion of progesterone and 17OHP into 11-deoxycorticosterone and 11-deoxycortisol, respectively. ^{[4] [33]} This process is done through hydroxylation at C-21 position. ^[34] It was described in at least 1953 that impaired steroid hydroxylation at C-21 position happens in congenital adrenal hyperplasia and is accompanied by excessive amounts of 17OHP that leads to virilism. ^[35]

In the insufficiency of 21-hydroxylase to participate in the biosynthesis of cortisol, the 21-hydroxylation in the zona fasciculata of the adrenal cortex is impaired, so 17OHP and progesterone will not be properly converted into 11-deoxycortisol and 11-deoxycorticosterone, respectively − the precursors for cortisol and aldosterone. As the plasma concentration of cortisol and aldosterone decreases, ACTH levels increase, leading to excessive production and accumulation of cortisol precursors (especially 17OHP), which are eventually transferred to androsterone that is a feedstock for other androgens. ^[36] Other androgens may be additionally produced from 17OHP, due to its elevated levels, that leads, inter alia, to its 5α-reduction. ^[37] These additional androgens are produced via the so-called "backdoor pathway" (see red arrows on the diagram). ^{[38] [39]} For example, in this "backdoor" pathway, 5α-dihydrotestosterone is produced with roundabout of testosterone as an intermediate product. ^{[37] [40] [41]} Some of the androgens produced by the backdoor pathway are those that cannot be converted to estrogens by aromatase, causing prenatal virilization, ^[42] and making them the dominant androgens in classic 21-hydroxylase deficiency. ^{[8] [27]}

See also: Androgen backdoor pathway

Virilization of genetically female (XX) infants usually produces obvious genital ambiguity. Inside the pelvis, the ovaries are normal and since they have not been exposed to testicular anti-Müllerian hormone (AMH), the uterus, fallopian tubes, upper vagina, and other Müllerian structures are normally formed as well. However, the high levels of testosterone ^[43] in the blood can enlarge the phallus, partially or completely close the vaginal opening, enclose the urethral groove so that it opens at the base of the phallus, on the shaft or even at the tip like a boy. Testosterone can cause the labial skin to become as thin and rugate as a scrotum, ^{[44] [45]} but cannot produce palpable gonads (i.e., testes) in the folds. ^{[46] [47] [48] [49] [50] [51]}

Thus, depending on the severity of hyperandrogenism, a female infant can be mildly affected, obviously ambiguous, or so severely virilized as to appear to be a male. Andrea Prader devised the following Prader scale as a way of describing the degree of virilization. ^[52]

• An infant at stage 1 has a mildly large clitoris and slightly reduced vaginal opening size. This degree may go unnoticed or may be simply assumed to be within normal variation.
• Stages 2 and 3 represent progressively more severe degrees of virilization. The genitalia are obviously abnormal to the eye, with a phallus intermediate in size and a small vaginal opening.
• Stage 4 looks more male than female, with an empty scrotum and a phallus the size of a normal penis, but not quite free enough of the perineum to be pulled onto the abdomen toward the umbilicus (i.e., what is termed a chordee in a male). The single small urethral/vaginal opening at the base or on the shaft of the phallus would be considered a hypospadias in a male. X-rays taken after dye injection into this opening reveal the internal connection with the upper vagina and uterus. This common opening can predispose to urinary obstruction and infection.
• Stage 5 denotes complete male virilization, with a normally formed penis with the urethral opening at or near the tip. The scrotum is normally formed but empty. The internal pelvic organs include normal ovaries and uterus, and the vagina connects internally with the urethra as in Stage 4. These infants are not visibly ambiguous, and are usually assumed to be ordinary boys with undescended testes. In most cases, the diagnosis of CAH is not suspected until signs of salt-wasting develop a week later. ^{[53] [54] [55] [56]}

When the genitalia are determined to be ambiguous at birth, CAH is one of the leading diagnostic possibilities. Evaluation reveals the presence of a uterus, extreme elevation of 17OHP, ^[57] levels of testosterone ^[43] approaching or exceeding the male range ^[58] but low AMH levels. The karyotype is that of an ordinary female: 46,XX. With this information, the diagnosis of CAH is readily made and female sex confirmed. ^{[53] [59] [60] [61] [62]}

See also: Ambiguous genitalia

Evaluation of ambiguous genitalia is described in detail elsewhere. In most cases it is possible to confirm and assign female sex within 12–36 hours of birth. The exception are the rare, completely virilized genetic females (Prader stage 5), who present the most challenging assignment and surgery dilemmas. ^{[63] [64]}

When the degree of ambiguity is obvious, corrective surgery is usually offered and performed, but reconstructive surgery on infant genitalia has controversies. ^{[65] [66] [67]}

See also: § Sex assignment issues and controversies

Reduced fertility

Testicular adrenal rest tumors

Infertility observed in adult males with classica CAH has been associated with testicular adrenal rest tumors (TART) that may originate during childhood. ^[68] Delayed diagnosis of CAH was associated with a higher risk of developing TART, which may be attributable to poor disease control early in life, ^[69] emphasizing the need of early detection and management of CAH, and, once CAH is detected, detection and management of TART. ^[70] TART in prepubertal males with classical CAH could be found during childhood (20%). Martinez-Aguayo et al. reported differences in markers of gonadal function in a subgroup of patients, especially in those with inadequate control. ^[71] Early glucocorticoid therapy may be beneficial to the reduction of TART. ^[72] Early detection and management of TART in CAH patients is important for preserving testicular function and preventing long-term complications that may impact fertility, ^[70] To avoid long-term complications in male patients with CAH, regular ultrasound examination of the scrotum is recommended, ^[70] especially in patients presenting with the most profound phenotypes of CAH and suboptimal endocrine regulation of the condition. ^[73] Subsequently, male subjects with nonclassic CAH rarely present with TARTs, and even though these tumors do not affect fertility and do not require regular ultrasound examination of the scrotum. ^[74]

Female fertility

Women with classical CAH have statistically reduced fertility, especially those with the salt-losing form. ^[75] Live birth rate is 33–50% in simple virilized form of CAH, and 0–10% in most severe salt-wasting form. In the nonclassical form of CAH the live birth is 63–90%, similar to the age-matched control groups. ^[76]

Sex assignment issues and controversies

Classical CAH leads to female pseudohermaphroditism at birth, and is the most common case of sex ambiguity, the second one is mixed gonadal dysgenesis. Most commonly, at birth, the phallus enlarges, so it is larger than normal female but smaller than normal male. Instead of separate urethral and vaginal openings, there is an urogenital sinus that is often covered by tissue resulting from the posterior fusion of the labioscrotal ridges. Therefore, different degrees of external genital abnormalities can be found, ranging from normal perineum to penile urethra. ^[76]

There are no difficulties assigning appropriate sex for most infants with CAH. Genetic males have normal male genitalia and gonads and simply need hormone replacement. Most virilized females are assigned and raised as girls even if their genitalia are ambiguous or look more male than female. They have normal ovaries and uterus and potential fertility with hormone replacement and surgery. The complex issues encountered in appropriate sex assignment for severely virilized XX infants have contributed to a deeper understanding of gender identity and sexual orientation. Consequently, this matter remains an ongoing subject of debate within medical discourse. ^{[77] [78] [79]}

Until the 1950s, some virilized XX infants were assigned and raised as girls, and some as boys. Most developed gender identities congruent with their sex of rearing. In a few cases of male rearing, a sex reassignment was attempted in mid-childhood when newly discovered karyotyping revealed "female" chromosomes. These reassignments were rarely successful, leading New Zealand American psychologist John Money and other influential psychologists and physicians to conclude that gender identity was (1) unrelated to chromosomes, (2) primarily a result of social learning, and (3) could not be easily changed after infancy. ^{[77] [78]}

By the 1960s, CAH was well understood, karyotyping was routine, and standard management was to assign and raise all children with CAH according to their gonads and karyotypes, no matter how virilized. Markedly virilized girls were usually referred to a pediatric surgeon, often a pediatric urologist for a reconstructive vaginoplasty and clitoral reduction or recession—surgery to create or enlarge a vaginal opening and reduce the size or protrusion of the clitoris. This approach was designed to preserve fertility for both sexes and remains the standard management, but two aspects of this management have been challenged: assignment of completely virilized genetic females and the value and age of corrective surgery. ^{[80] [77]}

The first questions about assignment were raised in the early 1980s when Money and others reported an unexpectedly high rate of failure to achieve normal adult sexual relationships (i.e., heterosexual orientation, marriage, and children) in grown women with CAH (though all had female gender identities). However, the sample was small, and results seemed interpretable in many ways: selection bias, early hormone effects on orientation, or sexual dysfunction created by residual body abnormalities or by the genital surgery itself. From a perspective two decades later, the report was one of the first pieces of evidence that the standard management paradigm was not always producing hoped-for outcomes. ^{[80] [81]}

Despite these concerns, no significant opposition to standard management arose until the mid-1990s, when a confluence of evidence and opinion from several sources led to a re-examination of outcomes. Several intersex support and advocacy groups (e.g., the Intersex Society of North America) began to publicly criticize infant genital surgery based on unsatisfactory outcomes of some adults who had been operated on as infants. Their complaints were that they had reduced ability to enjoy sexual relations or that they resented not having had the choice of gender assignment or surgical reconstruction left until they were old enough to participate. ^{[82] [83]}

See also: History of intersex surgery

In 1997, influential articles by Reiner, Diamond, and Sigmundson advocated consideration of (1) male sex assignment in the unambiguously male XX infants (most of whom are considered male until the CAH is recognized at 1–2 weeks of age), and (2) delaying reconstructive surgery until the patient is old enough to participate in the decision. ^[63]

Although the standard management approach remains "standard", more time and consideration are being given in many cases to explaining alternatives to parents and a small number of XX children with unambiguously male external genitalia are again being raised as boys. ^{[84] [85] [86] [87] [88]}

Late onset (nonclassical) CAH

Main article: Late onset congenital adrenal hyperplasia

In the milder, nonclassical form of CAH, the androgen excess is subtle enough that virilization is not apparent or goes unrecognized at birth and in early childhood. However, androgen levels are above normal and slowly rise during childhood, producing noticeable effects between 2 and 9 years of age. ^[89]

Appearance of pubic hair in mid-childhood is the most common feature that leads to evaluation and diagnosis of the late onset (nonclassical) CAH. Other accompanying features are likely to be tall stature and accelerated bone age (often 3–5 years ahead). Often present are increased muscle mass, acne, and adult body odor. In boys the penis will be enlarged. Mild clitoral enlargement may occur in girls, and sometimes a degree of prenatal virilization is recognized that may have gone unnoticed in infancy. ^{[89] [90]}

The principal goals of treatment of nonclassical CAH are to preserve as much growth as possible and to prevent central precocious puberty if it has not already been triggered. These are more difficult challenges than in CAH detected in infancy because moderate levels of androgens will have had several years to advance bone maturation and to trigger central puberty before the disease is detected. ^{[91] [89]}

A diagnosis of nonclassical CAH is usually confirmed by discovering extreme elevations of 17OHP along with moderately high testosterone levels. A cosyntropin stimulation test may be needed in mild cases, but usually the random levels of 17OHP are high enough to confirm the diagnosis. ^{[92] [93] [94]}

Elevated 17OHP may activate androgen "backdoor" pathway, that leads to excess of 5α-dihydrotestosterone and other potent androgens. ^{[95] [96]}

See also: Androgen backdoor pathway

The mainstay of treatment of symptomos of hyperandrogenism is suppression of androgens of adrenal origin by a glucocorticoid such as hydrocortisone. Mineralocorticoid is only added in cases where the plasma renin activity is high. ^{[97] [98] [99]} Most patients that have the nonclassic form do not require any glucocorticoid replacement therapy, ^[4] as cortisol synthesis impairment is mild but clinically silent. ^{[100] [101] [12]} Patients usually have the same baseline but lower peak cortisol levels comparing to healthy controls. ^{[102] [103]} The exact degree of cortisol synthesis impairment depends on genotype. ^[104]

An important aspect of management of nonclassic CAH is suppression of central precocious puberty if it has begun. The usual clues to central puberty in boys are that the testes are pubertal in size, or that androgens of adrenal origin remain elevated even when the 17OHP has been reduced toward normal. In girls central puberty is less often a problem, but breast development would be the main clue. Central precocious puberty is suppressed when appropriate by leuprolide. ^{[105] [106] [107]}

As outlined above, recent additions to treatment to preserve growth include aromatase inhibition to slow bone maturation by reducing the amount of testosterone converted to estradiol, and use of blockers of estrogen for the same purpose. ^{[108] [109] [110] [111]}

Once adrenal suppression has been achieved, the patient needs stress steroid coverage as described above for significant illness or injury. ^[112]

Various variants of the CYP21A2 gene result various degrees of hyperandrogenism, some of which may be such a mild that they may not even cause problems in males and may not be recognized until adolescence or later in females. ^[113] Mild androgen effects in young women may include hirsutism, acne, or anovulation (which in turn can cause infertility). Testosterone levels in these women may be mildly elevated, or simply above average. Despite the prevailing notion that testosterone and 5α-dihydrotestosterone (DHT) are the primary human androgens, this notion only applies to healthy men. ^[114] Although testosterone has been traditionally used as a biomarker of hyperandrogenism, ^[115] it correlates poorly with clinical measurements of androgen excess. ^{[27] [114]} While testosterone levels can appear normal, ignoring the alternative androgen pathways may lead to diagnostic errors since hyperandrogenism may be caused by potent androgens such as DHT produced by a backdoor pathway and 11-oxygenated androgens. ^{[27] [116] [117]} It may be that 11-ketotestosterone is the main androgen in women since it circulates at similar level to testosterone and may ^[118] or may not ^{[119] [120]} decline with age as testosterone does. While 11-ketodihydrotestosterone (11KDHT) is equipotent to DHT, circulating levels of 11KDHT are lower than DHT. ^[27] Unlike testosterone and androstenedione, 11-oxygenated androgens are not known to be aromatized to estrogens in the human body. ^{[27] [42] [121]}

These clinical features are those of polycystic ovary syndrome (PCOS), and a small percentage of women with PCOS are found to have late onset CAH when investigated. Late onset CAH is often misdiagnosed as PCOS. ^[122]

Late onset CAH is often diagnosed in the context of infertility assessment in women. Diagnosis of late onset CAH may be suspected from a high 17OHP level, but some cases are so mild that the elevation is only demonstrable after cosyntropin stimulation. Treatment may involve a combination of very low dose glucocorticoid to reduce adrenal androgen production and any of various agents to block the androgen effects and/or induce ovulation. During the follicular phase of the menstrual cycle, progesterone accumulates along with 17OHP which can thin the endometrium and change cervical mucus in a manner similar to the effect of progestogen contraceptives, interferes with the normal menstrual cycle, which can lead to oligomenorrhea or amenorrhea ^[12] and impairs sperm penetration. ^[123] Abnormal endometrial development leads to decreased uterine receptivity, which also contributes to infertility. ^[124] Once attempting to conceive, most women with late onset CAH will become pregnant within a year with or without treatment, but they have an increased risk of miscarriage. ^{[125] [12]}

Late onset CAH was originally characterized in 1957 by French biochemist Jacques Decourt, ^[126] but the association with mild 21-hydroxylase deficiency called nonclassical 21-hydroxylase deficiency, which is characterized by diverse hyperandrogenic symptoms appearing postnatally in males and females, was first described in 1979 by Maria New. ^[127] New since then have studied ways to reduce androgen excess and found out that treatment with dexamethasone 0.25 mg orally every evening reversed acne and irregular menstruation in 3 months, but hirsutism required up to 30 months. ^{[128] [129]} Dexamethasone has glucocorticoid activity, and potent ACTH-suppression properties within the hypothalamic–pituitary–adrenal axis. ^{[130] [131]} Lower ACTH leads to reduced production of all the steroids, including androgens. According to 2018 Clinical Practice Guideline, glucocorticoid treatment is not recommended in asymptomatic individuals, however, if the symptoms of androgen excess are sufficient, dexamethasone treatment may be prescribed. ^[4] Another treatment option is oral contraceptive pills. ^{[132] [100]}

Genetics

21-hydroxylase CAH is inherited in an autosomal recessive fashion

Main article: 21-Hydroxylase

The CYP21A2 gene for the P450c21 enzyme (also known as 21-hydroxylase) is at 6p21.3, ^[133] amid genes HLA B and HLA DR coding for the major human histocompatibility loci (HLA). The protein-coding CYP21A2 gene may be accompanied with one or several copies of the nonfunctional pseudogene CYP21A1P. ^{[134] [36]} Scores of abnormal alleles of CYP21A2 have been documented, most arising from recombinations of homologous regions of CYP21A2 and CYP21A1P. ^[36] The 21-hydroxylase deficiency may be caused by macrodeletions of about 30 Kb, which includes not only most of the 5′ region of the CYP21A2 gene, but also all of the C4B gene and 3′ regions of the CYP21A1P pseudogene. Duplications of CYP21A1P pseudogene and C4B gene are often associated with nonclassic 21-hydroxylase deficiency. ^[33]

Due to the high degree of homology between the CYP21A2 gene and the CYP21A1P pseudogene, and the complexity of the locus, research on the molecular level is difficult. ^[135]

Differences in residual enzyme activity of the various alleles account for the various degrees of severity of the disease. ^{[136] [137] [138]} Inheritance of all forms of 21-hydroxylase CAH is autosomal recessive, ^[4] except some mild disease-causing variants such as p.V281L that seem to exert dominant negative effects on enzymatic activity. ^[2]

Persons affected by any forms of the disease have two abnormal alleles, and both parents are usually heterozygotes (or carriers). When both parents carry an abnormal allele, each child has a 25% chance of having the disease, a 50% chance of being a carrier like the parents, and a 25% chance of having two normal genes. ^[4]

It is possible to test for heterozygosity by measuring 17OHP elevation after ACTH stimulation. ^[139]

More than 200 disease-causing variants within the CYP21A2 gene have been identified so far that lead to 21-hydroxylase deficiency. ^[140] Most patients have at least two of these variants present as compound heterozygous. ^{[141] [142] [143]}

There are some mild disease-causing variants that seem to exert dominant negative effects on enzymatic activity, even if present as single heterozygous. One example is a point mutation in exon 7 of CYP21A2, (p.V281L), which is commonly found in LOCAH-associated alleles. ^{[2] [135] [142]} Carriers for this mutation retain 20%–50% of 21-hydroxylase activity, ^{[144] [145]} but are at higher risk of symptoms of androgen excess than carriers of the severe mutations, ^[146] and had higher adrenocorticotropic hormone (ACTH) stimulated 17OHP, ^[147] suggesting that the mutant protein V281L enzyme co-expressed with the wild-type (healthy) enzyme resulted in an apparent dominant negative effect on the enzymatic activity. ^[148]

There is a good correlation between the genotype and phenotype. As a result, the CYP21A2 genotyping has high diagnostic value. However, the genotyping of the CYP21A2 gene is prone to errors, especially due to the closely located and highly homologous pseudogene CYP21A1P and the complex duplications, deletions and rearrangements within the chromosome 6p21.3. That's why CYP21A2 genotyping, interpretation of the results, and adequate genetic counseling for patients and their families requires deep understanding of CYP21A2 genetics. ^[36]

The CYP21A1P pseudogene retains 98% exonic sequence identity with the functional gene CYP21A2, ^{[149] [150]} and the high degree of sequence similarity between them indicates that these two genes are evolving in tandem through intergenic exchange of DNA. ^[151] Both genes are located on chromosome 6, in the major histocompatibility complex III (MHC class III) ^[152] close to the Complement component 4 genes C4A and C4B , the Tenascin X gene TNXB and STK19 . ^[153] MHC class III is the most gene-dense region of the human genome, containing many genes that yet have unknown function or structure. ^{[154] [152]}

The CYP21A2 gene is located within the RCCX cluster (an abbreviation composed of the names of the genes RP (a former name for STK19 serine/threonine kinase 19), ^{[155] [156]} C4 , CYP21 and TNX ), ^[157] which is the most complex gene cluster in the human genome. ^[158] The number of RCCX segments varies between one and four in a chromosome, ^[155] with the prevalence of approximately 15% for monomodular, 75% for bimodular (STK19-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB), ^{[156] [138]} and 10% for trimodular in Europeans. ^[159] The quadrimodular structure of the RCCX unit is very rare. ^{[160] [155] [159]} In a monomodular structure, all of the genes are functional i.e. protein-coding, but if a module count is two or more, there is only one copy of each functional gene rest being non-coding pseudogenes with the exception of the C4 gene which always has active copies. ^{[155] [159]}

Due to the high degree of homology between the CYP21A2 gene and the CYP21P1 pseudogene and the complexity of the locus, it is difficult to study the CYP21A2 gene at the molecular level, giving sometimes inaccurate or inconclusive results. ^[135] Targeted long-read sequencing method aims to improve the accuracy of the findings, ^[125] however, the clinical use of this method is limited. ^[161]

The cryptic form of (CAH) refers to a condition in which an individual is genetically determined to have the nonclassic variant of CAH but does not display any obvious symptoms. The term "cryptic" is used due to the lack of symptomatology in these individuals. Most males and some females with nonclassic CAH do not exhibit clinical signs or symptoms. However, the exact prevalence of asymptomatic individuals among those genetically identified with nonclassic CAH is currently unknown. Therefore, it is also uncertain what proportion of this population represents the cryptic form of CAH. ^[2]

Pathophysiology

Steroidogenesis: Deficiency in 21-hydroxylase (green vertical bar visible near the top center) leads to accumulation of progesterone and 17α-hydroxyprogesterone; excessive accumulation of these steroids leads to their conversion to androgens (lower left), whereas production of mineralcorticoids and glucocorticoids (top left), including cortisol, is reduced.

The enzyme P450c21, commonly referred to as 21-hydroxylase (21-OH), is embedded in the smooth endoplasmic reticulum of the cells of the adrenal cortex. It catalyzes hydroxylation of 17α-hydroxyprogesterone (17OHP) to 11-deoxycortisol in the glucocorticoid pathway, which starts from pregnenolone and finishes with cortisol. It also catalyzes hydroxylation of progesterone to 11-deoxycorticosterone (DOC) in the mineralocorticoid pathway on its way from pregnenolone to aldosterone. ^[162]

Deficient activity of this enzyme reduces the efficiency of cortisol synthesis, with consequent hyperplasia of the adrenal cortex and elevation of ACTH levels. ACTH stimulates uptake of cholesterol and synthesis of pregnenolone. Steroid precursors up to and including progesterone, 17α-hydroxypregnenolone, and especially 17OHP accumulate in the adrenal cortex and in circulating blood. Blood levels of 17OHP can reach 10-1000 times the normal concentration. ^[163]

Since 21-hydroxylase activity is not involved in synthesis of androgens, a substantial fraction of the large amounts of 17α-hydroxypregnenolone is diverted to synthesis of DHEA, androstenedione, and other androgens of adrenal origin beginning in the third month of fetal life in both sexes. ^[164]

Synthesis of aldosterone is also dependent on 21-hydroxylase activity. Although fetal production is impaired, it causes no prenatal effects, as the placental connection allows maternal blood to "dialyze" the fetus and maintain both electrolyte balance and blood volume. ^[165]

Diagnosis

Since CAH is an autosomal recessive disease, most children with CAH are born to parents unaware of the risk and with no family history. Each child will have a 25% chance of being born with the disease. ^[4]

Classification

The condition can be classified into "salt-wasting", "simple virilizing", and "nonclassical" forms. ^[4]

Type	Sex steroid effects	Other effects
Severe 21-hydroxylase deficiency causes salt-wasting CAH	The most common cause of ambiguous genitalia due to prenatal virilization of genetically female (XX) infants.	Life-threatening vomiting and dehydration occurring within the first few weeks of life. Aldosterone and cortisol levels are both reduced.
Moderate 21-hydroxylase deficiency is referred to as simple virilizing CAH	Typically is recognized as causing virilization of prepubertal children.	Cortisol is reduced, but aldosterone is not.
Still milder forms of 21-hydroxylase deficiency are referred to as nonclassical CAH	Can cause androgen effects and infertility in adolescent and adult women.	Cortisol is mildly reduced depending on genotype, [104] but aldosterone is not.
Patients who are genetically found to have nonclassical CAH but are asymptomatic	No symptoms of androgen excess, levels of androgens are within the normal range.	Neither aldosterone nor cortisol are reduced.

The salt-wasting and simple virilizing types are sometimes grouped together as "classical". ^[166]

Newborn screening

Conditions justifying newborn screening for any disorder include (1) a simple test with an acceptable sensitivity and specificity, (2) a dire consequence if not diagnosed early, (3) an effective treatment if diagnosed, and (4) a frequency in the population high enough to justify the expense. In the last decade more states and countries are adopting newborn screening for salt-wasting CAH due to 21-hydroxylase deficiency, which leads to death in the first month of life if not recognized. ^{[57] [23]}

The salt-wasting form of CAH has an incidence of 1 in 15,000 births and is potentially fatal within a month if untreated. Steroid replacement is a simple, effective treatment. However, the screening test itself is less than perfect, because of low specificity and high levels of false positives, meaning that the tests sometimes give incorrect results, saying the baby has CAH when they actually do not. This can make the family worried and spend money unnecessarily on hospital visits and extra tests that are not needed. ^[167] For the newborn screening, levels of 17α-hydroxyprogesterone (17OHP) are typically measured against predetermined cutoff, which depends on the measurement method. ^{[163] [57]} While the 17OHP level is easy to measure and sensitive (rarely missing real cases), the test has a poorer specificity, giving high rates of false positives. ^[167] Screening programs in the United States have reported that 99% of positive screens turn out to be false positives upon investigation of the infant. ^{[168] [169] [170]} This is a higher rate of false positives than the screening tests for many other congenital metabolic diseases. ^{[163] [57]}

Measurement 17OHP by LC-MS/MS reduces false positive rate in newborn screening in comparison to measurement by immunoassays. 17OHP steroid precursors and their sulphated conjugates which are present in the first two days after birth in healthy infants and longer in pre-term neonates, cross-react in immunoassays with 17OHP, giving falsely high 17OHP levels. ^{[171] [172]}

When a positive result is detected, the infant must be referred to a pediatric endocrinologist to confirm or disprove the diagnosis. Since most infants with salt-wasting CAH become critically ill by 2 weeks of age, the evaluation must be done rapidly despite the high false positive rate. ^[173]

Levels of 17OHP, androstenedione, and cortisol may play a role in screening. ^[174]

Additional markers

While 17OHP with or without ACTH stimulation is the main marker for 21-hydroxylase deficiency, other markers have been proposed, with various degrees of acceptance: ^{[175] [176]}

• 21-Deoxycortisol is elevated in 21-hydroxylase deficiency. ^[177] However, it is not elevated in preterm infants or in other forms of congenital adrenal hyperplasia. Unlike 17OHP, 21-deoxycortisol is not produced in the gonads and is uniquely adrenal-derived. ^[12] Consequently, 21-deoxycortisol it is a more specific marker of the 21-hydroxylase deficiency than 17OHP. Even so, 21-deoxycortisol measurement has not been commonly performed by laboratories until 2019. ^{[178] [179]} Still, 21-deoxycortisol can be a key screening marker for 21-hydroxylase deficiency in newborn screening. ^{[177] [180]}
• 21-Deoxycorticosterone, also known as 11β-hydroxyprogesterone (11β-OHP), have been proposed as a marker in 1987. ^{[181] [182]} A study in 2017 has shown that in subjects with 21-hydroxylase deficiency, serum 11β-OHP concentrations range from 0.012 to 3.37 ng/mL, while in control group it was below detection limit of 0.012 ng/mL. ^[38] This marker did not gain acceptance due to the fact that the test for the levels of this steroid is not routinely offered by diagnostic laboratories. ^[183]
• Progesterone levels are higher in CAH subjects. A study has revealed that serum progesterone concentrations in boys (10 days to 18 years old) with 21-hydroxylase deficiency reached levels up to 10.14 ng/mL, i.e. similar to female luteal values, while in the control group of boys average level was 0.07 ng/mL (0.22 nmol/L), with values ranging from 0.05 to 0.40 ng/mL. ^[38] The authors of the study propose to use progesterone as an additional marker for 21-hydroxylase deficiency. The study shows that the progesterone levels in CAH and non-CAH females are the same as in CAH and non-CAH males respectively – it is the condition that affects progesterone levels, not the sex, but for women between menarch and menopause, progesterone should be measured in days 3–5 of the cycle to have diagnostic value – the same condition also applies for 17OHP. The specificity of progesterone as a marker of 21-hydroxylase deficiency, as opposed to deficiency of other enzymes involved in steroid pathways, is still not well studied. ^{[184] [185] [186]}
• Cortisol is one of the two main final products of 21-hydroxylase, and the deficiency of this enzyme may lead to a certain degree of cortisol deficiency. Cortisol levels are lower in CAH subjects, on average, ^[38] however, in milder cases cortisol levels can be normal, but, this has not been yet well studied. Cortisol measurement using immunoassays is prone to cross-reactivity with various substances including 21-deoxycortisol that raises due to 21-hydroxylase deficiency, leading to falsely high cortisol levels when the true cortisol is actually low. ^{[187] [188]} The selectivity offered by liquid chromatography-tandem mass spectrometry (LC-MS/MS) has largely overcome these limitations. ^{[189] [190]} As a result, the use of LC-MS/MS instead of immunoassays in cortisol measurement aims to provide greater specificity. ^{[177] [191]}
• 11-Deoxycortisol is a direct product of 17α-hydroxyprogesterone, with 21-hydroxylase catalyzing the reaction, and an intermediate product towards cortisol pathway. Reduced 21-hydroxylase activity leads to decreased levels of 11-deoxycortisol, but not all laboratories specify minimum reference value it, since it is mostly used as a biomarker for 11β-hydroxylase deficiency, where 11-deoxycortisol levels increase dramatically, so the laboratories may only specify the maximum reference value. ^[175]

Treatment

Prenatal treatment

Clinical Practice Guideline advise that clinicians continue to regard prenatal therapy as experimental. ^[4]

Because the period during which fetal genitalia may become virilized begins about 6 weeks after conception, prenatal treatment to avoid virilization must be started by 6 to 7 weeks. ^[4]

Application of dexamethasone in prenatal treatment

Adrenal glands of female fetuses with CAH begin producing excess androgens ^[192] by the 9th week of gestation. ^{[193] [194]} The most important aspects of virilization (urogenital closure and phallic urethra) occur between 8 and 12 weeks. ^[195] Theoretically, if enough glucocorticoid could be supplied to the fetus to reduce adrenal androgen biosynthesis by the 9th week, virilization could be prevented and the difficult decision about timing of surgery avoided. ^{[193] [196]}

The challenge of preventing severe virilization of girls is twofold: detection of CAH at the beginning of the pregnancy, and delivery of an effective amount of glucocorticoid to the fetus without causing harm to the mother. ^{[197] [198] [199]}

The first problem has not yet been entirely solved, but it has been shown that if dexamethasone is taken by a pregnant woman, enough can cross the placenta to suppress fetal adrenal function. ^[200]

At present no program screens for risk in families who have not yet had a child with CAH. For families desiring to avoid virilization of a second child, the current strategy is to start dexamethasone as soon as a pregnancy has been confirmed even though at that point the chance that the pregnancy is a girl with CAH is only 12.5%. Dexamethasone is taken by the mother each day until it can be safely determined whether she is carrying an affected girl. ^[201]

Whether the fetus is an affected girl can be determined by chorionic villus sampling at 9–11 weeks of gestation, or by amniocentesis at 15–18 weeks gestation. In each case the fetal sex can be determined quickly, and if the fetus is a male the dexamethasone can be discontinued. If female, fetal DNA is analyzed to see if she carries one of the known abnormal alleles of the CYP21 gene. If so, dexamethasone is continued for the remainder of the pregnancy at a dose of about 1 mg daily. ^[201]

Most mothers who have followed this treatment plan have experienced at least mild cushingoid effects from the glucocorticoid but have borne daughters whose genitalia are much less virilized. ^[201]

Dexamethasone is used as an off-label early prenatal treatment for the symptoms of CAH in female fetuses, but it does not treat the underlying congenital disorder. A 2007 Swedish clinical trial found that treatment may cause cognitive and behavioural defects, but the small number of test subjects means the study cannot be considered definitive. A 2012 American study found no negative short-term outcomes, but "lower cognitive processing in CAH girls and women with long-term dexamethasone exposure." ^[202] Administration of pre-natal dexamethasone has been the subject of controversy over issues of informed consent and because treatment must predate a clinical diagnosis of CAH in the female fetus, ^[203] especially because in utero dexamethasone may cause metabolic problems that are not evident until later in life; Swedish clinics ceased recruitment for research in 2010. ^[204]

The treatment has also raised concerns in LGBT and bioethics communities following publication of an essay posted to the forum of the Hastings Center, and research in the Journal of Bioethical Inquiry, which found that pre-natal treatment of female fetuses was suggested to prevent those fetuses from becoming lesbians after birth, may make them more likely to engage in "traditionally" female-identified behaviour and careers, and more interested in bearing and raising children. Citing a known attempt by a man using his knowledge of the fraternal birth order effect to avoid having a homosexual son by using a surrogate, the essayists (Professor Alice Dreger of Northwestern University's Feinberg School of Medicine, Professor Ellen Feder of American University and attorney Anne Tamar-Mattis) suggest that prenatal dexamethasone treatments constitute the first known attempt to use in utero protocols to reduce the incidence of homosexuality and bisexuality in humans. ^{[205] [206]} Research on the use of prenatal hormone treatments to prevent homosexuality stretches back to the early 1990s or earlier. ^[207]

Since CAH is a recessive gene, both the mother and father must be recessive carriers of CAH for a child to have CAH. Due to advances in modern medicine, those couples with the recessive CAH genes have an option to prevent CAH in their offspring through preimplantation genetic diagnosis (PGD). In PGD, the egg is fertilized outside the woman's body in a Petri dish (IVF). On the 3rd day, when the embryo has developed from one cell to about 4 to 6 cells, one of those cells is removed from the embryo without harming the embryo. The embryo continues to grow until day 5 when it is either frozen or implanted into the mother. Meanwhile, the removed cell is analyzed to determine if the embryo has CAH. If the embryo is determined to have CAH, the parents may make a decision as to whether they wish to have it implanted in the mother or not. ^[192]

Meta-analysis of the studies supporting the use of dexamethasone on CAH at-risk fetuses found "less than one half of one percent of published 'studies' of this intervention were regarded as being of high enough quality to provide meaningful data for a meta-analysis. Even these four studies were of low quality ... in ways so slipshod as to breach professional standards of medical ethics" ^[206] and "there were no data on long-term follow-up of physical and metabolic outcomes in children exposed to dexamethasone". ^[208]

Long-term management of CAH

Management of infants and children with CAH is complex and warrants long-term care in a pediatric endocrine clinic. After the diagnosis is confirmed, and any salt-wasting crisis averted or reversed, major management issues include:^{[ citation needed ]}

1. Initiating and monitoring hormone replacement
2. Stress coverage, crisis prevention, parental education
3. Reconstructive surgery
4. Optimizing growth
5. Optimizing androgen suppression and fertility in women with CAH

Management of adults with CAH should take into consideration side effects of long-term glucocorticoid exposure, such as cardiovascular morbidities. ^[99]

Hormone replacement

The primary goals of hormone replacement are to protect from adrenal insufficiency and to suppress the excessive adrenal androgen production. ^{[209] [210]}

Glucocorticoids are provided to all children and adults with all but the mildest and latest-onset forms of CAH. The glucocorticoids provide a reliable substitute for cortisol, thereby reducing ACTH levels. Reducing ACTH also reduces the stimulus for continued hyperplasia and overproduction of androgens. In other words, glucocorticoid replacement is the primary method of reducing the excessive adrenal androgen production in both sexes. A number of glucocorticoids are available for therapeutic use. Hydrocortisone or liquid prednisolone is preferred in infancy and childhood, and prednisone or dexamethasone are often more convenient for adults. ^{[209] [176]}

The glucocorticoid dose is typically started at the low end of physiologic replacement (6–12 mg/m²) ^[4] but is adjusted throughout childhood to prevent both growth suppression from too much glucocorticoid and androgen escape from too little. Serum levels of 17OHP, testosterone, androstenedione, and other adrenal steroids are followed for additional information, but may not be entirely normalized even with optimal treatment. As regular monitoring is needed, patients can be monitored non-invasively by measuring 17OHP and androstenedione in saliva. ^[211] (See Glucocorticoid for more on this topic.) However, the currently used glucocorticoid therapy methods may lead to unphysiological doses that, in addition to the problems caused by overexposure of androgens, can harm health. Various clinical results, besides the steroids, require regular monitoring. The negative consequences are primarily the result of non-physiological glucocorticoid replacement. ^[212] During illness or physical or mental stress, the demand for cortisol can increase, sometimes leading to adrenal crises. As current glucocorticoid therapy regiments fail to replicate the physiologic circadian rhythm and the glucocorticoids are often administered at a higher dose to treat androgen excess, the long-term consequences of the therapy, such as decreased bone density and an increased cardiometabolic risk profile, ^[99] should be addressed; other consequences of CAH such as impaired quality of life and affected mental health should be taken into consideration; periodic assessments and monitoring of patients should take place in specialized centers to detect and treat potential complications early. ^[136] Clinical studies are underway to find ways to better mimic the normal circadian rhythm of cortisol secretion and to reduce the total dose of glucocorticoids. ^[213]

Mineralocorticoids are replaced in all infants with salt-wasting and in most patients with elevated renin levels. Fludrocortisone is the only pharmaceutically available mineralocorticoid and is usually used in doses of 0.05 to 2 mg daily. ^[4] Electrolytes, renin, and blood pressure levels are followed to optimize the dose. ^[214]

Stress coverage, crisis prevention, parental education

Even after diagnosis and initiation of treatment, a small percentage of children and adults with infancy or childhood onset CAH die of adrenal crisis. ^[4] Deaths from this are entirely avoidable if the child and family understand that the daily glucocorticoids cannot be allowed to be interrupted by an illness. When a person is well, missing a dose, or even several doses, may produce little in the way of immediate symptoms. However, glucocorticoid needs are increased during illness and stress, and missed doses during an illness such as the ifluenza or viral gastroenteritis can lead within hours to reduced blood pressure, shock, and death. ^{[215] [216]}

To prevent this, all persons taking replacement glucocorticoids are taught to increase their doses in the event of illness, surgery, severe injury, or severe exhaustion. More importantly, they are taught that vomiting warrants an injection within hours of hydrocortisone (e.g., SoluCortef) or other glucocorticoid. This recommendation applies to both children and adults. Because young children are more susceptible to vomiting illnesses than adults, pediatric endocrinologists usually teach parents how to give hydrocortisone injections. ^{[216] [209]}

As an additional precaution, persons with adrenal insufficiency are advised to wear a medical identification tag or carry a wallet card to alert those who may be providing emergency medical care of the urgent need for glucocorticoids. ^[217]

Reconstructive surgery

Surgery need never be considered for genetically male (XY) infants because the excess androgens do not produce anatomic abnormality. However, surgery for severely virilized XX infants is often performed and has become a subject of debate. ^[218]

Surgical reconstruction of abnormal genitalia has been offered to parents of severely virilized girls with CAH since the first half of the 20th century. The purposes of surgery have generally been a combination of the following: ^[219]

1. To make the external genitalia look more female than male;
2. To make it possible for these girls to participate in normal sexual intercourse when they grow up;
3. To improve their chances of fertility;
4. To reduce the frequency of urinary infections. ^[219]

In the 1950s and 1960s, surgery often involved clitorectomy (removal of most of the clitoris), an operation that also reduced genital sensation. In the 1970s, new operative methods were developed to preserve innervation and clitoral function. However, a number of retrospective surveys in the last decade suggest that (1) sexual enjoyment is reduced in many women even after nerve-sparing procedures, and (2) women with CAH who have not had surgery also have a substantial rate of sexual dysfunction. (See Intersex surgery for an overview of procedures and potential complications, and History of intersex surgery for a fuller discussion of the controversies.) Many patient advocates and surgeons argue for deferring surgery until adolescence or later, while some surgeons continue to argue that infant surgery has advantages. ^[220]

Optimizing growth in CAH

It is unclear what concentration of adrenal androgens is best for normal growth, puberty, and bone health. ^[221]

One of the challenging aspects of long-term management is optimizing growth so that a child with CAH achieves his or her height potential because both undertreatment and overtreatment can reduce growth or the remaining time for growth. While glucocorticoids are essential for health, dosing is always a matter of approximation. In even mildly excessive amounts, glucocorticoids slow growth. On the other hand, adrenal androgens are readily converted to estradiol, which accelerates bone maturation and can lead to early epiphyseal closure. This narrow target of optimal dose is made more difficult to obtain by the imperfect replication of normal diurnal plasma cortisol levels produced by 2 or 3 oral doses of hydrocortisone. ^{[222] [223]} As a consequence, average height losses of about 4 inches (10 cm) have been reported with traditional management. ^[4]

Traditionally, pediatric endocrinologists have tried to optimize growth by measuring a child every few months to assess current rate of growth, by checking the bone age every year or two, by periodically measuring 17OHP and testosterone levels as indicators of adrenal suppression, and by using hydrocortisone for glucocorticoid replacement rather than longer-acting prednisone or dexamethasone. ^[163]

The growth problem is even worse in the simple virilizing forms of CAH which are detected when premature pubic hair appears in childhood, because the bone age is often several years advanced at the age of diagnosis. While a boy (or girl) with simple virilizing CAH is taller than peers at that point, he will have far fewer years remaining to grow, and may go from being a very tall 7-year-old to a 62-inch 13-year-old who has completed growth. Even with adrenal suppression, many of these children will have already had central precocious puberty triggered by the prolonged exposure of the hypothalamus to the adrenal androgens and estrogens. If this has begun, it may be advantageous to suppress puberty with a gonadotropin-releasing hormone agonist such as leuprolide to slow continuing bone maturation. ^{[224] [225] [226]}

In recent years some newer approaches to optimizing growth have been researched and are beginning to be used. It is possible to reduce the effects of androgens on the body by blocking the receptors with an antiandrogen such as flutamide and by reducing the conversion of testosterone to estradiol. This conversion is mediated by aromatase and can be inhibited by aromatase blockers such as testolactone. Blocking the effects and conversions of estrogens will allow use of lower doses of glucocorticoids with less risk of acceleration of bone maturation. Other proposed interventions have included bilateral adrenalectomy to remove the androgen sources, or growth hormone treatment to enhance growth. ^[227]

Preventing hyperandrogenism and optimizing fertility

As growth ends, management in girls with CAH changes focus to optimizing reproductive function. Both excessive androgens from the adrenals and excessive glucocorticoid treatment can disrupt ovulation, resulting in irregularity of menses or amenorrhea, as well as infertility. Continued monitoring of hormone balance and careful readjustment of glucocorticoid dose can usually restore fertility, but as a group, women with CAH have a lower fertility rate than a comparable population. ^[4]

Classical CAH has little effect on male fertility unless an adult stops taking his glucocorticoid medication entirely for an extended time, in which case excessive adrenal androgens may reduce testicular production as well as spermatogenesis. ^[4] Regarding nonclassic CAH, glucocorticoid therapy is typically not necessary for lifelong management. However, in certain cases, this treatment may be required to address fertility issues such as oligomenorrhea, amenorrhea, or difficulty conceiving. About 90% of women with nonclassic CAH remain undiagnosed. Once attempting to conceive, approximately 83% of women win nonclassic CAH successfully achieve pregnancy within one year, irrespective of whether they receive glucocorticoid therapy or not, but the therapy reduces risk of miscarriage. ^[12]

Psychosexual development and issues

Nearly all mammals display sex-dimorphic reproductive and sexual behavior (e.g., lordosis and mounting in rodents). Much research has made it clear that prenatal and early postnatal androgens play a role in the differentiation of most mammalian brains. Experimental manipulation of androgen levels in utero or shortly after birth can alter adult reproductive behavior. ^[4]

Girls and women with CAH constitute the majority of genetic females with normal internal reproductive hormones who have been exposed to male levels of androgens throughout their prenatal lives. Milder degrees of continuing androgen exposure continue throughout childhood and adolescence as a consequence of the imperfections of current glucocorticoid treatment for CAH. The psychosexual development of these girls and women has been analyzed as evidence of the role of androgens in human sex-dimorphic behaviors. ^[4]

In comparison to unaffected individuals, patients with classical CAH exhibit a greater prevalence of anxiety disorders, depressive disorders, alcohol misuse, personality disorders, and suicidal tendencies in males, while females are more prone to adjustment disorders. ^[12] In comparison to the general population, individuals with CAH have a higher prevalence of substance abuse and attention deficit–hyperactivity disorder (ADHD). This is particularly observed in females with the most severe null genotype and males who receive a diagnosis after the neonatal period. ^[12]

Girls with CAH have repeatedly been reported to spend more time with "sex-atypical" toys and "rough-and-tumble" play than unaffected sisters. These differences continue into adolescence, as expressed in social behaviors, leisure activities, and career interests. Interest in babies and becoming mothers is significantly lower by most measures. ^[12] Avoidance of romantic relationships is common in women and men with classical CAH. ^[12]

Gender identity of girls and women with CAH is most frequently observed to be female. Sexual orientation is more mixed, though the majority are heterosexual. ^[12] In one study, 27% of women with CAH were rated as bisexual in their orientations. ^[228]

A 2020 survey of 57 females with life-long experience of CAH and 132 parents of females with CAH in the United States revealed that majority of participants do not consider females with CAH to be intersex, and oppose a legal intersex designation of females with CAH. ^[229]

Cognitive effects are less clear. Altered fetal and postnatal exposure to androgens, as well as glucocorticoid therapy, affect brain development and function. Compared to healthy girls, those with classical CAH have more aggressive behavior but have better spatial navigation abilities, and the amygdala activation patterns differ between affected and healthy girls. Glucocorticoid therapy in CAH impairs working memory and causes brain changes, including white matter hyperintensities, suggesting a reduction in white matter structural integrity. ^[12] Cognitive impairment, when observed, has occasionally been attributed to hypoglycemia and electrolyte imbalances at the initial presentation. ^[12] A 2023 population-based cohort study of 714 patients with classical CAH and 71400 control subjects predict that patients with CAH have an increased prevalence of injuries and accidents, especially females, but the cause is not known. ^[230]

The increased prevalence of depressive and anxiety disorders, along with the prescription of antidepressants by medical practitioners, among youth with CAH in comparison to the general population indicates the potential necessity for screening for symptoms of depression and anxiety in this specific population. ^[231]

Given that people with CAH exhibit a higher incidence and severity of behavioral symptoms, ^[12] and that the manifestation of these behavioral problems can be attributed to excessive endogenous androgen exposure and side effects of glucucorticoid therapy, ^[12] emphasis should be placed on early optimization of CAH management to mitigate the psychological ramifications that may ensue. ^[232]

Prognosis

The outcomes and prognosis for CAH (Congenital Adrenal Hyperplasia) can vary depending on several factors, such as the specific type of CAH, its severity, early detection, and proper management. With appropriate medical care and ongoing treatment, individuals with CAH can lead healthy lives. Consistent monitoring and adherence to treatment are crucial for optimal outcomes. ^[4]

Children with CAH often experience increased height during early childhood, but their final adult height tends to be shorter than expected. Advanced bone age and early fusion of growth plates due to excess androgens contribute to this outcome. Additionally, glucocorticoid treatment for CAH can affect growth and result in decreased final height. Experimental treatments using growth hormone and luteinizing hormone-releasing hormone analogs have shown some success in increasing average height gains by approximately 7.3 cm. Most children with CAH have normal neuropsychological development, although there may be differences in gendered play activities influenced by prenatal sex steroid exposure. ^[1]

While bone density is typically normal in most patients, metabolic abnormalities such as obesity, insulin resistance, dyslipidemia (abnormal blood lipid levels), and polycystic ovarian syndrome are more prevalent either due to the disease itself or long-term glucocorticoid treatment. ^[4]

Fertility is possible for both males and females with CAH but may be reduced due to multiple factors encompassing biology, psychology, social influences, and sexual aspects. ^[4]

Management of CAH requires collaboration among different subspecialty professionals considering the complex nature of the disease's complications and long-term consequences. ^[1]

Incidence and variants

According to most studies, the global incidence of classical forms range from about 1:14,000 to 1:18,000 births, based on newborn screening programs and national case registries, but this situation is more common in small genetically isolated populations with small gene pools. ^[4] 10% of patients with classical forms of CAH have CAH-X syndrome, that is marked by the presence of CAH features along with features indicative of hypermobility-type Ehlers-Danlos syndrome. This condition results from a contiguous gene deletion that impacts both CYP21A2 and TNXB genes. ^{[233] [234]}

The incidence of nonclassical forms of CAH is 1:200 to 1:1000 based on various estimates, and is also higher in groups people with a high rate of marriage between relatives, up to 1:50. ^{[4] [235] [128]} Nonclassic CAH may be identified incidentally during the assessment of oligomenorrhea, amenorrhea, and infertility in females. However, a significant proportion, approximately 90%, of women with nonclassic CAH remain undiagnosed. As for men with nonclassic CAH, their asymptomatic nature commonly leads to underdiagnosis. ^[12]

History

In 19th Century, cases of CAH were reported, leading to the understanding that the adrenal gland influenced sexual phenotypes as well as being mysteriously required for survival. ^[236]

In 1865, CAH in its non-salt-wasting form was thoroughly described for the first time by a Neapolitan pathologist Luigi De Crecchio. ^[237] However, significant strides in understanding and treating the condition have been made over the years.^{[ citation needed ]}

In the early 20th Century, numerous adrenal steroids were isolated, and bioassays eventually distinguished glucocorticoids, mineralocorticoids, and androgens. ^[236]

In 1950, Wilkins, Bartter, and Albright revolutionized clinical endocrinology with the use of cortisone to treat CAH and ushered in a productive era of pediatric adrenal research. Through careful clinical research, Wilkins established modern methods of treating CAH. ^[236]

In 1957, Alfred Bongiovanni noticed a defect in 21-hydroxylation in CAH, followed by defects in 3β-hydroxysteroid dehydrogenase and 11β-hydroxylase. ^[236]

P450 enzymes were described from 1962 to 1964, and 21-hydroxylation was the first identified activity of P450s. ^[236]

In the last quarter of the 20th Century, notable scholars who have contributed to the development of CAH knowledge include Hans Selye, who studied stress responses and adrenal function, ^[236] as well as Maria New, who conducted extensive research on prenatal treatment options for CAH.

From 1984 to 2004, the techniques of molecular genetics were applied to elucidate the genetic and biochemical bases of CAH. ^[236]

Society and culture

Society's understanding of CAH can vary widely, leading to different perceptions and attitudes toward individuals with the condition. Lack of awareness or misconceptions about CAH may contribute to stigma or discrimination. ^{[238] [239]}

Discussions around intersex conditions have evolved over time as societal understanding has progressed. There is consensus that classical CAH is an intersex condition. However, for the nonclassical CAH, there is a debate on whether it can be considered an intersex condition. Anne Fausto-Sterling, an American sexologist, in a 2000 book "Sexing the Body" came up with an estimate that people with intersex conditions account for 1.7% of the general population. ^[240] This estimate is cited by a number of prominent intersex advocacy organizations. ^{[241] [242] [243] [244]} Of these intersex individuals, according to Fausto-Sterling, 88% have nonclassical CAH. ^[240] Leonard Sax, an American psychologist and a family physician, criticized these figures in a review published in 2002 in The Journal of Sex Research, stating that from the clinician's perspective, nonclassical CAH is not an intersex condition. ^[245] Including nonclassical CAH in intersex prevalence estimates has been cited by Joel Best, is a professor of sociology and criminal justice, in a 2013 book "Stat-Spotting: A Field Guide to Identifying Dubious Data" as an example of misleading statistical practice. ^[246]

Different cultural contexts may shape views on gender identity, sexuality, and medical interventions for intersex conditions. Individuals with visible differences or unique health needs associated with CAH may face social stigmatization due to a lack of awareness, prejudice, or preconceived notions about intersexuality. ^{[247] [248] [249] [250]}

See also: § Sex assignment issues and controversies

Activists, such as Hida Viloria, who was born with a form of CAH, advocate for compassionate care for people born intersex. ^{[251] [252]}

Research directions

Main article: Gene therapy

Gene therapy is an experimental therapeutic approach that aims to correct the underlying genetic defect responsible for a particular condition. In the context of CAH, caused by mutations in the CYP21A2 gene, gene replacement therapy involves introducing a functional copy of this gene into the cells where this gene is expressed. The goal is to normalize the production of 21-hydroxylase, the enzyme encoded by CYP21A2. Providing a working copy of this gene may improve adrenal hormone synthesis and subsequently normalize cortisol and aldosterone production. ^[253]

Currently, gene replacement therapy for CAH is still at an early stage of research and development. Various approaches are being explored, including using viral vectors carrying a healthy copy of the CYP21A2 gene to deliver it into target cells. Another approach is based on utilizing human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) to generate steroid-producing cells that can potentially replace or supplement dysfunctional adrenal tissue in individuals with CAH. However, it remains unclear how new approaches can be tested, as there are even no experimental models yet for this disease for gene therapy. ^[254]

See also

• Inborn errors of steroid metabolism
• Congenital adrenal hyperplasia
• Adrenal insufficiency
• Disorders of sexual development
• Intersexuality, pseudohermaphroditism, and ambiguous genitalia
• 21-Hydroxylase

References

•  This article incorporates text available under the CC BY-SA 4.0 license.

1. Burdea L, Mendez MD (July 2023). "21-Hydroxylase Deficiency". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID   29630216.
2. Hannah-Shmouni F, Morissette R, Sinaii N, Elman M, Prezant TR, Chen W, et al. (November 2017). "Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians". Genetics in Medicine. 19 (11): 1276–1279. doi:10.1038/gim.2017.46. PMC   5675788 . PMID   28541281.
3. Dumić M, Brkljacić L, Mardesić D, Plavsić V, Lukenda M, Kastelan A (July 1985). "'Cryptic' form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in the Yugoslav population". Acta Endocrinol (Copenh). 109 (3): 386–92. doi:10.1530/acta.0.1090386. PMID   2992207.
4. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. (November 2018). "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology and Metabolism. 103 (11): 4043–4088. doi:10.1210/jc.2018-01865. PMC   6456929 . PMID   30272171.
5. Neves Cruz J, da Costa KS, de Carvalho TA, de Alencar NA (March 2020). "Measuring the structural impact of mutations on cytochrome P450 21A2, the major steroid 21-hydroxylase related to congenital adrenal hyperplasia". Journal of Biomolecular Structure & Dynamics. 38 (5): 1425–1434. doi:10.1080/07391102.2019.1607560. PMID   30982438. S2CID   115195169.
6. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI (July 1985). "High frequency of nonclassical steroid 21-hydroxylase deficiency". American Journal of Human Genetics. 37 (4): 650–667. PMC   1684620 . PMID   9556656.
7. Krone N, Arlt W (April 2009). "Genetics of congenital adrenal hyperplasia". Best Practice & Research. Clinical Endocrinology & Metabolism. 23 (2): 181–192. doi:10.1016/j.beem.2008.10.014. PMC   5576025 . PMID   19500762.
8. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, et al. (May 2016). "Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency". European Journal of Endocrinology. 174 (5): 601–609. doi:10.1530/EJE-15-1181. PMC   4874183 . PMID   26865584.
9. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland HJ, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, New M, Yau M, Lekarev O, Lin-Su K, Parsa A, Pina C, Yuen T, Khattab A (15 March 2017). Congenital Adrenal Hyperplasia. MDText.com, Inc. PMID   25905188.
10. Nordenström A, Lajic S, Falhammar H (August 2022). "Long-Term Outcomes of Congenital Adrenal Hyperplasia". Endocrinology and Metabolism. 37 (4): 587–598. doi:10.3803/EnM.2022.1528. PMC   9449109 . PMID   35799332.
11. Dauber A, Kellogg M, Majzoub JA (August 2010). "Monitoring of therapy in congenital adrenal hyperplasia". Clinical Chemistry. 56 (8): 1245–1251. doi: 10.1373/clinchem.2010.146035 . PMID   20558634.
12. Merke DP, Auchus RJ (September 2020). "Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency". The New England Journal of Medicine. 383 (13): 1248–1261. doi:10.1056/NEJMra1909786. PMID   32966723. S2CID   221884108.
13. Trapp CM, Speiser PW, Oberfield SE (June 2011). "Congenital adrenal hyperplasia: an update in children". Current Opinion in Endocrinology, Diabetes, and Obesity. 18 (3): 166–170. doi:10.1097/MED.0b013e328346938c. PMC   3638875 . PMID   21494138.
14. White PC, Speiser PW (June 2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocrine Reviews. 21 (3): 245–291. doi: 10.1210/edrv.21.3.0398 . PMID   10857554.
15. Kulshreshtha B, Eunice M, Ammini AC (July 2012). "Pubertal development among girls with classical congenital adrenal hyperplasia initiated on treatment at different ages". Indian Journal of Endocrinology and Metabolism. 16 (4): 599–603. doi: 10.4103/2230-8210.98018 . PMC   3401763 . PMID   22837923.
16. Mueller SC, Temple V, Oh E, VanRyzin C, Williams A, Cornwell B, et al. (August 2008). "Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH)". Psychoneuroendocrinology. 33 (7): 973–980. doi:10.1016/j.psyneuen.2008.04.005. PMC   2566857 . PMID   18675711.
17. Kung KT, Spencer D, Pasterski V, Neufeld S, Glover V, O'Connor TG, et al. (December 2016). "No relationship between prenatal androgen exposure and autistic traits: convergent evidence from studies of children with congenital adrenal hyperplasia and of amniotic testosterone concentrations in typically developing children". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 57 (12): 1455–1462. doi:10.1111/jcpp.12602. PMC   6100761 . PMID   27460188.
18. Antal Z, Zhou P (July 2009). "Congenital adrenal hyperplasia: diagnosis, evaluation, and management". Pediatrics in Review. 30 (7): e49–e57. doi:10.1542/pir.30-7-e49. PMID   19570920. S2CID   30104550.
19. Fahmida Z, Quamrul H, Nurun N (2015). "Congenital Adrenal Hyperplasia (Salt Wasting)". DS (Child) H J.
20. Nimkarn S, Lin-Su K, Berglind N, Wilson RC, New MI (January 2007). "Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia". The Journal of Clinical Endocrinology and Metabolism. 92 (1): 137–142. doi: 10.1210/jc.2006-0964 . PMID   17032723.
21. Varness TS, Allen DB, Hoffman GL (October 2005). "Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls". The Journal of Pediatrics. 147 (4): 493–498. doi:10.1016/j.jpeds.2005.04.035. PMID   16227036.
22. Chan CL, McFann K, Taylor L, Wright D, Zeitler PS, Barker JM (July 2013). "Congenital adrenal hyperplasia and the second newborn screen". The Journal of Pediatrics. 163 (1): 109–13.e1. doi:10.1016/j.jpeds.2013.01.002. PMID   23414665.
23. Grosse SD, Van Vliet G (2007). "How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia?". Hormone Research. 67 (6): 284–291. doi: 10.1159/000098400 . PMID   17199092. S2CID   21497680.
24. Hindmarsh PC (April 2009). "Management of the child with congenital adrenal hyperplasia". Best Practice & Research. Clinical Endocrinology & Metabolism. 23 (2): 193–208. doi:10.1016/j.beem.2008.10.010. PMID   19500763.
25. Fleming L, Knafl K, Knafl G, Van Riper M (October 2017). "Parental management of adrenal crisis in children with congenital adrenal hyperplasia". Journal for Specialists in Pediatric Nursing. 22 (4). doi:10.1111/jspn.12190. PMC   5884098 . PMID   28771930.
26. Pang S, Clark A (1990). "Newborn screening, prenatal diagnosis, and prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Trends in Endocrinology and Metabolism. 1 (6): 300–307. doi:10.1016/1043-2760(90)90068-e. PMID   18411135. S2CID   21880131.
27. Masiutin M, Yadav M (2023). "Alternative androgen pathways". WikiJournal of Medicine. 10: X. doi: 10.15347/WJM/2023.003 . S2CID   257943362.
28. O'Shaughnessy PJ, Antignac JP, Le Bizec B, Morvan ML, Svechnikov K, Söder O, et al. (February 2019). Rawlins E (ed.). "Alternative (backdoor) androgen production and masculinization in the human fetus". PLOS Biology. 17 (2): e3000002. doi: 10.1371/journal.pbio.3000002 . PMC   6375548 . PMID   30763313.
29. Barnard L, Gent R, van Rooyen D, Swart AC (November 2017). "Adrenal C11-oxy C₂₁ steroids contribute to the C11-oxy C₁₉ steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone". The Journal of Steroid Biochemistry and Molecular Biology. 174: 86–95. doi:10.1016/j.jsbmb.2017.07.034. PMID   28774496. S2CID   24071400.
30. Kumar V, Abbas AK, Aster JC, Cotran RS, Robbins SL (2014). Robbins and Cotran pathologic basis of disease (Ninth ed.). Philadelphia, PA: Elsevier/Saunders. p. 1128. ISBN   978-1-4557-2613-4. OCLC   879416939.
31. du Toit T, Swart AC (September 2021). "Turning the spotlight on the C11-oxy androgens in human fetal development". J Steroid Biochem Mol Biol. 212: 105946. doi:10.1016/j.jsbmb.2021.105946. PMID   34171490. S2CID   235603586.
32. Murphy BE, Sebenick M, Patchell ME (January 1980). "Cortisol production and metabolism in the human fetus and its reflection in the maternal urine". J Steroid Biochem. 12: 37–45. doi:10.1016/0022-4731(80)90248-4. PMID   7191459.
33. Araújo RS, Mendonca BB, Barbosa AS, Lin CJ, Marcondes JA, Billerbeck AE, Bachega TA (October 2007). "Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency". The Journal of Clinical Endocrinology and Metabolism. 92 (10): 4028–4034. doi: 10.1210/jc.2006-2163 . PMID   17666484.
34. Neunzig J, Milhim M, Schiffer L, Khatri Y, Zapp J, Sánchez-Guijo A, et al. (March 2017). "The steroid metabolite 16(β)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1". The Journal of Steroid Biochemistry and Molecular Biology. 167: 182–191. doi:10.1016/j.jsbmb.2017.01.002. PMID   28065637. S2CID   36860068.
35. Jailer JW (May 1953). "Virilism". Bulletin of the New York Academy of Medicine. 29 (5): 377–394. PMC   1877295 . PMID   13032691.
36. Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W (October 2020). "EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency". European Journal of Human Genetics. 28 (10): 1341–1367. doi: 10.1038/s41431-020-0653-5 . PMC   7609334 . PMID   32616876. S2CID   220295067.
37. Fukami M, Homma K, Hasegawa T, Ogata T (April 2013). "Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development". Developmental Dynamics. 242 (4): 320–329. doi: 10.1002/dvdy.23892 . PMID   23073980. S2CID   44702659.
38. Fiet J, Le Bouc Y, Guéchot J, Hélin N, Maubert MA, Farabos D, Lamazière A (March 2017). "A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of Congenital Adrenal Hyperplasia". Journal of the Endocrine Society. 1 (3): 186–201. doi:10.1210/js.2016-1048. PMC   5686660 . PMID   29264476.
39. Auchus RJ (2010). "Management of the adult with congenital adrenal hyperplasia". International Journal of Pediatric Endocrinology. 2010: 614107. doi: 10.1155/2010/614107 . PMC   2896848 . PMID   20613954.
40. van Rooyen D, Gent R, Barnard L, Swart AC (April 2018). "The in vitro metabolism of 11β-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway". The Journal of Steroid Biochemistry and Molecular Biology. 178: 203–212. doi:10.1016/j.jsbmb.2017.12.014. PMID   29277707. S2CID   3700135.
41. Gueux B, Fiet J, Galons H, Boneté R, Villette JM, Vexiau P, et al. (January 1987). "The measurement of 11 beta-hydroxy-4-pregnene-3,20-dione (21-deoxycorticosterone) by radioimmunoassay in human plasma". primary. Journal of Steroid Biochemistry. 26 (1): 145–150. doi:10.1016/0022-4731(87)90043-4. PMID   3546944.
42. Nagasaki K, Takase K, Numakura C, Homma K, Hasegawa T, Fukami M (November 2020). "Foetal virilisation caused by overproduction of non-aromatisable 11-oxygenated C19 steroids in maternal adrenal tumour". Human Reproduction. 35 (11): 2609–2612. doi:10.1093/humrep/deaa221. PMID   32862221.
43. Rauh M, Gröschl M, Rascher W, Dörr HG (June 2006). "Automated, fast and sensitive quantification of 17 alpha-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line extraction". Steroids. 71 (6): 450–458. doi:10.1016/j.steroids.2006.01.015. PMID   16569417. S2CID   11605597.
44. Glaser RL, Dimitrakakis C, Messenger AG (February 2012). "Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study". The British Journal of Dermatology. 166 (2): 274–278. doi:10.1111/j.1365-2133.2011.10655.x. PMC   3380548 . PMID   21967243.
45. Gharahdaghi N, Phillips BE, Szewczyk NJ, Smith K, Wilkinson DJ, Atherton PJ (2020). "Links Between Testosterone, Oestrogen, and the Growth Hormone/Insulin-Like Growth Factor Axis and Resistance Exercise Muscle Adaptations". Frontiers in Physiology. 11: 621226. doi: 10.3389/fphys.2020.621226 . PMC   7844366 . PMID   33519525.
46. Ogilvy-Stuart AL, Brain CE (May 2004). "Early assessment of ambiguous genitalia". Archives of Disease in Childhood. 89 (5): 401–407. doi:10.1136/adc.2002.011312. PMC   1719899 . PMID   15102623.
47. Anhalt H, Neely EK, Hintz RL (June 1996). "Ambiguous genitalia". Pediatrics in Review. 17 (6): 213–220. doi:10.1542/pir.17-6-213. PMID   8857201. S2CID   261302604.
48. Corona G, Maggi M (December 2022). "The role of testosterone in male sexual function". Reviews in Endocrine & Metabolic Disorders. 23 (6): 1159–1172. doi:10.1007/s11154-022-09748-3. PMC   9789013 . PMID   35999483.
49. Kim HW, Yoo SY, Oh S, Jeon TY, Kim JH (March 2020). "Ultrasonography of Pediatric Superficial Soft Tissue Tumors and Tumor-Like Lesions". Korean Journal of Radiology. 21 (3): 341–355. doi:10.3348/kjr.2019.0343. PMC   7039727 . PMID   32090527.
50. Sultan C, Paris F, Jeandel C, Lumbroso S, Galifer RB (August 2002). "Ambiguous genitalia in the newborn". Seminars in Reproductive Medicine. 20 (3): 181–188. doi:10.1055/s-2002-35382. PMID   12428198. S2CID   21484378.
51. Cabrera SM, Rogol AD (May 2013). "Testosterone exposure in childhood: discerning pathology from physiology". Expert Opinion on Drug Safety. 12 (3): 375–388. doi:10.1517/14740338.2013.782000. PMID   23517636. S2CID   24307618.
52. "Andrea Prader | RCP Museum". history.rcplondon.ac.uk. Retrieved 2023-08-01.
53. González R, Ludwikowski BM (2016). "Should CAH in Females Be Classified as DSD?". Frontiers in Pediatrics. 4: 48. doi: 10.3389/fped.2016.00048 . PMC   4865481 . PMID   27242977.
54. de Jesus LE, Costa EC, Dekermacher S (November 2019). "Gender dysphoria and XX congenital adrenal hyperplasia: how frequent is it? Is male-sex rearing a good idea?". Journal of Pediatric Surgery. 54 (11): 2421–2427. doi:10.1016/j.jpedsurg.2019.01.062. PMID   30905417. S2CID   85501467.
55. Kudela G, Gawlik A, Koszutski T (May 2020). "Early Feminizing Genitoplasty in Girls with Congenital Adrenal Hyperplasia (CAH)-Analysis of Unified Surgical Management". International Journal of Environmental Research and Public Health. 17 (11): 3852. doi: 10.3390/ijerph17113852 . PMC   7312042 . PMID   32485822.
56. Jones CL, Houk CP, Barroso JU, Lee PA (April 2022). "Fully Masculinized 46,XX Individuals with Congenital Adrenal Hyperplasia: Perspective Regarding Sex of Rearing and Surgery". International Journal of Fertility & Sterility. 16 (2): 128–131. doi:10.22074/IJFS.2021.532602.1144. PMC   9108292 . PMID   35639647.
57. Prentice P (December 2021). "Guideline review: congenital adrenal hyperplasia clinical practice guideline 2018". Archives of Disease in Childhood. Education and Practice Edition. 106 (6): 354–357. doi:10.1136/archdischild-2019-317573. PMID   33272921. S2CID   227258191.
58. Li JR, Goodman X, Cho J, Holditch-Davis D (October 2021). "The Variability and Determinants of Testosterone Measurements in Children: A Critical Review". Biological Research for Nursing. 23 (4): 646–657. doi:10.1177/10998004211017323. PMC   8726425 . PMID   34000839.
59. Zwayne N, Chawla R, van Leeuwen K (August 2023). "Caring for Patients With Congenital Adrenal Hyperplasia Throughout the Lifespan". Obstetrics and Gynecology. 142 (2): 257–268. doi:10.1097/AOG.0000000000005263. PMID   37473408. S2CID   259996994.
60. Amais DS, da Silva TE, Barros BA, de Andrade JG, de Lemos-Marini SH, de Mello MP, et al. (December 2022). "Sex dimorphism of weight and length at birth: evidence based on disorders of sex development". Annals of Human Biology. 49 (7–8): 274–279. doi:10.1080/03014460.2022.2134452. PMID   36218438. S2CID   252816435.
61. Dehneh N, Jarjour R, Idelbi S, Alibrahem A, Al Fahoum S (October 2022). "Syrian females with congenital adrenal hyperplasia: a case series". Journal of Medical Case Reports. 16 (1): 371. doi: 10.1186/s13256-022-03609-y . PMC   9569117 . PMID   36242011.
62. Khattab A, Yau M, Qamar A, Gangishetti P, Barhen A, Al-Malki S, et al. (January 2017). "Long term outcomes in 46, XX adult patients with congenital adrenal hyperplasia reared as males". The Journal of Steroid Biochemistry and Molecular Biology. 165 (Pt A): 12–17. doi:10.1016/j.jsbmb.2016.03.033. PMID   27125449. S2CID   21521508.
63. Dessens AB, Slijper FM, Drop SL (August 2005). "Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia". Archives of Sexual Behavior. 34 (4): 389–397. doi:10.1007/s10508-005-4338-5. PMID   16010462. S2CID   11328239.
64. Riedl S, Röhl FW, Bonfig W, Brämswig J, Richter-Unruh A, Fricke-Otto S, et al. (February 2019). "Genotype/phenotype correlations in 538 congenital adrenal hyperplasia patients from Germany and Austria: discordances in milder genotypes and in screened versus prescreening patients". Endocrine Connections. 8 (2): 86–94. doi:10.1530/EC-18-0281. PMC   6365666 . PMID   30620712.
65. Szymanski KM, Whittam B, Kaefer M, Frady H, Casey JT, Tran VT, et al. (April 2018). "Parental decisional regret and views about optimal timing of female genital restoration surgery in congenital adrenal hyperplasia". Journal of Pediatric Urology. 14 (2): 156.e1–156.e7. doi:10.1016/j.jpurol.2017.11.012. PMID   29330019.
66. Liao L, Sun M, Wang F, Pan S, Wu X, Huang X (December 2022). "Clinical characteristics of female patients diagnosed with congenital adrenal hyperplasia and plastic-esthetic related thoughts: a retrospective study". Neuro Endocrinology Letters. 43 (7–8): 378–384. PMID   36720126.
67. Fernandez N, Chavarriaga J, Pérez J (2021). "Complete corporeal preservation clitoroplasty: new insights into feminizing genitoplasty". International Braz J Urol. 47 (4): 861–867. doi:10.1590/S1677-5538.IBJU.2020.0839. PMC   8321476 . PMID   33848081.
68. Eyer de Jesus L, Paz de Oliveira AP, Porto LC, Dekermacher S (October 2023). "Testicular adrenal rest tumors - Epidemiology, diagnosis and treatment". J Pediatr Urol. 20 (1): 77–87. doi:10.1016/j.jpurol.2023.10.005. PMID   37845103. S2CID   263817094.
69. Schröder MA, Neacşu M, Adriaansen BP, Sweep FC, Ahmed SF, Ali SR, Bachega TA, Baronio F, Birkebæk NH, de Bruin C, Bonfig W, Bryce J, Clemente M, Cools M, Elsedfy H, Globa E, Guran T, Güven A, Amr NH, Janus D, Taube NL, Markosyan R, Miranda M, Poyrazoğlu Ş, Rees A, Salerno M, Stancampiano MR, Vieites A, de Vries L, Yavas Abali Z, Span PN, Claahsen-van der Grinten HL (October 2023). "Hormonal control during infancy and testicular adrenal rest tumor development in males with congenital adrenal hyperplasia: a retrospective multicenter cohort study". Eur J Endocrinol. 189 (4): 460–468. doi: 10.1093/ejendo/lvad143 . PMID   37837609.
70. Tuladhar S, Katwal S, Joshi HO, Yadav B, Bhusal A, Bhandari S (December 2023). "Testicular adrenal rest tumors (TART) secondary to congenital adrenal hyperplasia: A case report emphasizing early detection and management". Radiology Case Reports. 18 (12): 4351–4356. doi:10.1016/j.radcr.2023.09.006. PMC   10542771 . PMID   37789918.
71. Martinez-Aguayo A, Rocha A, Rojas N, García C, Parra R, Lagos M, et al. (Chilean Collaborative Testicular Adrenal Rest Tumor Study Group) (December 2007). "Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia". The Journal of Clinical Endocrinology and Metabolism. 92 (12): 4583–4589. doi: 10.1210/jc.2007-0383 . PMID   17895312.
72. Zhang Q, Zang L, Zhang CY, Gu WJ, Li B, Jia XF, et al. (January 2022). "[Diagnosis and treatment of 21-hydroxylase deficiency with testicular adrenal rest tumors:a report of three cases and literature review]". Zhonghua Nei Ke Za Zhi (in Chinese). 61 (1): 72–76. doi:10.3760/cma.j.cn112138-20210718-00488 (inactive 2024-04-26). PMID   34979773.
73. Ortolano R, Cassio A, Alqaisi RS, Candela E, Di Natale V, Assirelli V, Bernardini L, Bortolamedi E, Cantarelli E, Corcioni B, Renzulli M, Balsamo A, Baronio F (August 2023). "Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia: Study of a Cohort of Patients from a Single Italian Center". Children. 10 (9): 1457. doi: 10.3390/children10091457 . PMC   10528159 . PMID   37761418.
74. Adriaansen BPH, Schröder MAM, Span PN, Sweep FCGJ, van Herwaarden AE, Claahsen-van der Grinten HL (2022). "Challenges in treatment of patients with non-classic congenital adrenal hyperplasia". Frontiers in Endocrinology. 13: 1064024. doi: 10.3389/fendo.2022.1064024 . PMC   9791115 . PMID   36578966.
75. Hirschberg AL, Gidlöf S, Falhammar H, Frisén L, Almqvist C, Nordenskjöld A, Nordenström A (January 2021). "Reproductive and Perinatal Outcomes in Women with Congenital Adrenal Hyperplasia: A Population-based Cohort Study". The Journal of Clinical Endocrinology and Metabolism. 106 (2): e957–e965. doi: 10.1210/clinem/dgaa801 . PMID   33135723.
76. Acién P, Acién M (November 2020). "Disorders of Sex Development: Classification, Review, and Impact on Fertility". Journal of Clinical Medicine. 9 (11): 3555. doi: 10.3390/jcm9113555 . PMC   7694247 . PMID   33158283.
77. Orozco-Poore C, Keuroghlian AS (June 2023). "Neurological Considerations for "Nerve-Sparing" Cosmetic Genital Surgeries Performed on Children with XX Chromosomes Diagnosed with 21-Hydroxylase Congenital Adrenal Hyperplasia and Clitoromegaly". LGBT Health. 10 (8): 567–575. doi:10.1089/lgbt.2022.0160. PMID   37319358. S2CID   259173363.
78. Hamori CA (October 2022). "Female Aesthetic Genital Procedures". Clinics in Plastic Surgery. 49 (4): ix. doi:10.1016/j.cps.2022.07.003. PMID   36162947. S2CID   252527170.
79. Hamori CA (October 2022). "The Aesthetic Genital Consultation: Inquiry to Scheduling". Clinics in Plastic Surgery. 49 (4): 435–445. doi:10.1016/j.cps.2022.06.006. PMID   36162938. S2CID   252526513.
80. Money J (2002). "Amative orientation: the hormonal hypothesis examined". Journal of Pediatric Endocrinology & Metabolism. 15 (7): 951–957. doi:10.1515/jpem.2002.15.7.951. PMID   12199338. S2CID   43116615.
81. Money J (2000). "Outcome Research in Pediatric Psychoendocrinology and Sexology". Therapeutic Outcome of Endocrine Disorders. Springer New York, NY. pp. 1–6. doi:10.1007/978-1-4612-1230-0_1. ISBN   978-1-4612-7052-2.
82. Behrens KG (October 2020). "A principled ethical approach to intersex paediatric surgeries". BMC Med Ethics. 21 (1): 108. doi: 10.1186/s12910-020-00550-x . PMC   7597036 . PMID   33121480.
83. "What it means to be intersex and why controversial surgeries are still allowed". 18 July 2023.
84. Radovick, Sally; MacGillivray, Margaret H., eds. (2003). "Management of Infants Born with Ambiguous Genitalia". Pediatric Endocrinology. Contemporary Endocrinology. Humana Press. pp. 429–449. doi:10.1007/978-1-59259-336-1. ISBN   978-1-61737-268-1.
85. Lerman SE, McAleer IM, Kaplan GW (January 2000). "Sex assignment in cases of ambiguous genitalia and its outcome". Urology. 55 (1): 8–12. doi: 10.1016/s0090-4295(99)00398-2 . PMID   10654885.
86. Bangalore Krishna K, Houk CP, Lee PA (June 2017). "Pragmatic approach to intersex, including genital ambiguity, in the newborn". Seminars in Perinatology. 41 (4): 244–251. doi:10.1053/j.semperi.2017.03.013. PMID   28535943.
87. Thyen U, Lanz K, Holterhus PM, Hiort O (2006). "Epidemiology and initial management of ambiguous genitalia at birth in Germany". Hormone Research. 66 (4): 195–203. doi:10.1159/000094782. PMID   16877870. S2CID   24768524.
88. Ahmed SF, Rodie M (April 2010). "Investigation and initial management of ambiguous genitalia". Best Practice & Research. Clinical Endocrinology & Metabolism. 24 (2): 197–218. doi:10.1016/j.beem.2009.12.001. PMID   20541148. S2CID   205973113.
89. Brener A, Segev-Becker A, Weintrob N, Stein R, Interator H, Schachter-Davidov A, et al. (August 2019). "Health-Related Quality of Life in Children and Adolescents with Nonclassic Congenital Adrenal Hyperplasia". Endocrine Practice. 25 (8): 794–799. doi:10.4158/EP-2018-0617. PMID   31013157. S2CID   129942669.
90. Labarta JI, Bello E, Ruiz-Echarri M, Rueda C, Martul P, Mayayo E, Ferrández Longás A (March 2004). "Childhood-onset congenital adrenal hyperplasia: long-term outcome and optimization of therapy". Journal of Pediatric Endocrinology & Metabolism. 17 (Suppl 3): 411–422. PMID   15134301.
91. Jesić M, Jesić M, Sajić S, Maglajlić S, Necić S, Bojić V (October 2004). "[Nonclassic congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency]". Srpski Arhiv Za Celokupno Lekarstvo. 132 (Suppl 1): 106–108. doi: 10.2298/sarh04s1106j . PMID   15615479.
92. Nakhleh A, Saiegh L, Shehadeh N, Weintrob N, Sheikh-Ahmad M, Supino-Rosin L, et al. (2022). "Screening for non-classic congenital adrenal hyperplasia in women: New insights using different immunoassays". Frontiers in Endocrinology. 13: 1048663. doi: 10.3389/fendo.2022.1048663 . PMC   9871807 . PMID   36704043.
93. Bachelot G, Bachelot A, Bonnier M, Salem JE, Farabos D, Trabado S, et al. (February 2023). "Combining metabolomics and machine learning models as a tool to distinguish non-classic 21-hydroxylase deficiency from polycystic ovary syndrome without adrenocorticotropic hormone testing". Human Reproduction. 38 (2): 266–276. doi:10.1093/humrep/deac254. PMID   36427016.
94. Tsai WH, Wong CH, Dai SH, Tsai CH, Zeng YH (2020). "Adrenal Tumor Mimicking Non-Classic Congenital Adrenal Hyperplasia". Frontiers in Endocrinology. 11: 526287. doi: 10.3389/fendo.2020.526287 . PMC   7551200 . PMID   33117272.
95. Fiet J, Gueux B, Raux-DeMay MC, Kuttenn F, Vexiau P, Brerault JL, et al. (March 1989). "Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway". primary. The Journal of Clinical Endocrinology and Metabolism. 68 (3): 542–547. doi:10.1210/jcem-68-3-542. PMID   2537337.
96. Sumińska M, Bogusz-Górna K, Wegner D, Fichna M (June 2020). "Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report". International Journal of Molecular Sciences. 21 (13): 4622. doi: 10.3390/ijms21134622 . PMC   7369945 . PMID   32610579.
97. Pofi R, Bonaventura I, Duffy J, Maunsell Z, Shine B, Isidori AM, Tomlinson JW (August 2023). "Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy". Endocrine Connections. 12 (9). doi:10.1530/EC-23-0059. PMC   10448575 . PMID   37410094.
98. Foster C, Diaz-Thomas A, Lahoti A (2020). "Low prevalence of organic pathology in a predominantly black population with premature adrenarche: need to stratify definitions and screening protocols". International Journal of Pediatric Endocrinology. 2020: 5. doi: 10.1186/s13633-020-0075-8 . PMC   7061481 . PMID   32165891.
99. Charoensri S, Auchus RJ (October 2023). "Predictors of cardiovascular morbidities in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia". The Journal of Clinical Endocrinology and Metabolism. 109 (3): e1133–e1142. doi: 10.1210/clinem/dgad628 . PMID   37878953.
100. Witchel SF, Azziz R (2010). "Nonclassic congenital adrenal hyperplasia". International Journal of Pediatric Endocrinology. 2010: 625105. doi: 10.1155/2010/625105 . PMC   2910408 . PMID   20671993.
101. Dineen R, Martin-Grace J, Thompson CJ, Sherlock M (June 2020). "The management of glucocorticoid deficiency: Current and future perspectives". Clinica Chimica Acta; International Journal of Clinical Chemistry. 505: 148–159. doi:10.1016/j.cca.2020.03.006. PMID   32145273. S2CID   212629520.
102. Karachaliou FH, Kafetzi M, Dracopoulou M, Vlachopapadopoulou E, Leka S, Fotinou A, Michalacos S (December 2016). "Cortisol response to adrenocorticotropin testing in non-classical congenital adrenal hyperplasia (NCCAH)". Journal of Pediatric Endocrinology & Metabolism. 29 (12): 1365–1371. doi:10.1515/jpem-2016-0216. PMID   27849625. S2CID   43390012.
103. Chung S, Son GH, Kim K (May 2011). "Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1812 (5): 581–591. doi: 10.1016/j.bbadis.2011.02.003 . PMID   21320597.
104. Koren I, Weintrob N, Kebesch R, Majdoub H, Stein N, Naor S, Segev-Becker A (September 2023). "Genotype-Specific Cortisol Reserve in a Cohort of Subjects with Non-Classic Congenital Adrenal Hyperplasia (NCCAH)". J Clin Endocrinol Metab. 109 (3): 852–857. doi: 10.1210/clinem/dgad546 . PMID   37715965.
105. Klein KO, Dragnic S, Soliman AM, Bacher P (June 2018). "Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate". Journal of Pediatric Endocrinology & Metabolism. 31 (6): 655–663. doi:10.1515/jpem-2017-0523. PMID   29750651. S2CID   21666126.
106. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, Wilson DM (October 1992). "Two-year results of treatment with depot leuprolide acetate for central precocious puberty". The Journal of Pediatrics. 121 (4): 634–640. doi: 10.1016/s0022-3476(05)81162-x . PMID   1403402.
107. Soliman AT, AlLamki M, AlSalmi I, Asfour M (May 1997). "Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog". Metabolism. 46 (5): 513–517. doi:10.1016/s0026-0495(97)90186-4. PMID   9160816.
108. Goedegebuure WJ, Hokken-Koelega AC (2019). "Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report". Hormone Research in Paediatrics. 92 (3): 209–213. doi:10.1159/000501746. PMC   7050682 . PMID   31390647.
109. Halper A, Sanchez B, Hodges JS, Dengel DR, Petryk A, Sarafoglou K (July 2019). "Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue". Clinical Endocrinology. 91 (1): 124–130. doi:10.1111/cen.14009. PMID   31070802. S2CID   148569761.
110. Liu SC, Suresh M, Jaber M, Mercado Munoz Y, Sarafoglou K (2023). "Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia". Frontiers in Endocrinology. 14: 1101843. doi: 10.3389/fendo.2023.1101843 . PMC   10018749 . PMID   36936152.
111. Alghamdi A (2023). "Precocious Puberty: Types, Pathogenesis and Updated Management". Cureus. 15 (10): e47485. doi: 10.7759/cureus.47485 . PMC   10663169 . PMID   38021712.
112. El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP (June 2018). "Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology and Metabolism. 103 (6): 2336–2345. doi:10.1210/jc.2018-00208. PMC   6276663 . PMID   29584889.
113. Balagamage C, Arshad A, Elhassan YS, Ben Said W, Krone RE, Gleeson H, Idkowiak J (November 2023). "Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care". Clin Endocrinol (Oxf). doi: 10.1111/cen.14992 . PMID   37964596.
114. Turcu AF, Auchus RJ (June 2017). "Clinical significance of 11-oxygenated androgens". Current Opinion in Endocrinology, Diabetes, and Obesity. 24 (3): 252–259. doi:10.1097/MED.0000000000000334. PMC   5819755 . PMID   28234803.
115. Yang Y, Ouyang N, Ye Y, Hu Q, Du T, Di N, et al. (October 2020). "The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome". Reproductive Biomedicine Online. 41 (4): 734–742. doi:10.1016/j.rbmo.2020.07.013. PMID   32912651. S2CID   221625488.
116. Balsamo A, Baronio F, Ortolano R, Menabo S, Baldazzi L, Di Natale V, et al. (2020). "Congenital Adrenal Hyperplasias Presenting in the Newborn and Young Infant". Frontiers in Pediatrics. 8. Frontiers Media SA: 593315. doi: 10.3389/fped.2020.593315 . PMC   7783414 . PMID   33415088.
117. Kamrath C, Wettstaedt L, Boettcher C, Hartmann MF, Wudy SA (April 2018). "Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia". The Journal of Steroid Biochemistry and Molecular Biology. 178. Elsevier BV: 221–228. doi:10.1016/j.jsbmb.2017.12.016. PMID   29277706. S2CID   3709499.
118. Skiba MA, Bell RJ, Islam RM, Handelsman DJ, Desai R, Davis SR (November 2019). "Androgens During the Reproductive Years: What Is Normal for Women?". The Journal of Clinical Endocrinology and Metabolism. 104 (11): 5382–5392. doi: 10.1210/jc.2019-01357 . PMID   31390028. S2CID   199467054.
119. Nanba AT, Rege J, Ren J, Auchus RJ, Rainey WE, Turcu AF (July 2019). "11-Oxygenated C19 Steroids Do Not Decline With Age in Women". The Journal of Clinical Endocrinology and Metabolism. 104 (7): 2615–2622. doi:10.1210/jc.2018-02527. PMC   6525564 . PMID   30753518.
120. Davio A, Woolcock H, Nanba AT, Rege J, O'Day P, Ren J, et al. (August 2020). "Sex Differences in 11-Oxygenated Androgen Patterns Across Adulthood". The Journal of Clinical Endocrinology and Metabolism. 105 (8): e2921–e2929. doi:10.1210/clinem/dgaa343. PMC   7340191 . PMID   32498089.
121. Barnard L, Schiffer L, Louw du-Toit R, Tamblyn JA, Chen S, Africander D, et al. (March 2021). "11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool". Endocrinology. 162 (3). doi:10.1210/endocr/bqaa231. PMC   7814299 . PMID   33340399.
122. Chrousos GP, Loriaux DL, Mann DL, Cutler GB (February 1982). "Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease". Annals of Internal Medicine. 96 (2): 143–148. doi:10.7326/0003-4819-96-2-143. PMID   6977282.
123. Turcu AF, Auchus RJ (June 2015). "Adrenal steroidogenesis and congenital adrenal hyperplasia". Endocrinology and Metabolism Clinics of North America. 44 (2): 275–296. doi:10.1016/j.ecl.2015.02.002. PMC   4506691 . PMID   26038201.
124. Pignatelli D, Pereira SS, Pasquali R (2019). "Androgens in Congenital Adrenal Hyperplasia". Hyperandrogenism in Women. Frontiers of Hormone Research. Vol. 53. S.Karger AG. pp. 65–76. doi:10.1159/000494903. ISBN   978-3-318-06470-4. PMID   31499506. S2CID   202412336.
125. Guo X, Zhang Y, Yu Y, Zhang L, Ullah K, Ji M, Jin B, Shu J (2023). "Corrigendum: Getting pregnant with congenital adrenal hyperplasia: assisted reproduction and pregnancy complications. A systematic review and meta-analysis". Front Endocrinol (Lausanne). 14: 1269711. doi: 10.3389/fendo.2023.1269711 . PMC   10575760 . PMID   37842302.
126. Decourt J, Jayle MF, Baulieu E (May 1957). "[Clinically late virilism with excretion of pregnanetriol and insufficiency of cortisol production]" [Clinically late virilism with excretion of pregnanetriol and insufficiency of cortisol production]. Annales d'Endocrinologie (in French). 18 (3): 416–422. PMID   13470408.
127. New MI, Lorenzen F, Pang S, Gunczler P, Dupont B, Levine LS (February 1979). ""Acquired" adrenal hyperplasia with 21-hydroxylase deficiency is not the same genetic disorders as congenital adrenal hyperplasia". The Journal of Clinical Endocrinology and Metabolism. 48 (2): 356–359. doi:10.1210/jcem-48-2-356. PMID   218988.
128. New MI (November 2006). "Extensive clinical experience: nonclassical 21-hydroxylase deficiency". The Journal of Clinical Endocrinology and Metabolism. 91 (11): 4205–4214. doi: 10.1210/jc.2006-1645 . PMID   16912124.
129. Trapp CM, Oberfield SE (March 2012). "Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update". Steroids. 77 (4): 342–346. doi:10.1016/j.steroids.2011.12.009. PMC   3638754 . PMID   22186144.
130. Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (2000). Glucocorticoid Therapy and Adrenal Suppression. MDText.com. PMID   25905379.
131. Rabhan NB (December 1968). "Pituitary-adrenal suppression and Cushing's syndrome after intermittent dexamethasone therapy". Annals of Internal Medicine. 69 (6): 1141–1148. doi:10.7326/0003-4819-69-6-1141. PMID   4881892.
132. Matthews D, Cheetham T (March 2013). "What is the best approach to the teenage patient presenting with nonclassical congenital adrenal hyperplasia: should we always treat with glucocorticoids?". Clinical Endocrinology. 78 (3): 338–341. doi: 10.1111/cen.12065 . PMID   23039910. S2CID   24131309.
133. Trakakis E, Loghis C, Kassanos D (March 2009). "Congenital adrenal hyperplasia because of 21-hydroxylase deficiency. A genetic disorder of interest to obstetricians and gynecologists". Obstetrical & Gynecological Survey. 64 (3): 177–189. doi:10.1097/OGX.0b013e318193301b. PMID   19228439. S2CID   37242194.
134.  This article incorporates public domain material from "CYP21A2 cytochrome P450 family 21 subfamily A member 2 [ Homo sapiens (human) ]". Reference Sequence collection . National Center for Biotechnology Information.
135. Espinosa Reyes TM, Collazo Mesa T, Lantigua Cruz PA, Agramonte Machado A, Domínguez Alonso E, Falhammar H (November 2020). "Molecular diagnosis of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency". BMC Endocrine Disorders. 20 (1): 165. doi: 10.1186/s12902-020-00643-z . PMC   7653887 . PMID   33168061.
136. Tschaidse L, Quitter F, Hübner A, Reisch N (January 2022). "[Long-term morbidity in congenital adrenal hyperplasia]". Der Internist (in German). 63 (1): 43–50. doi:10.1007/s00108-021-01223-6. PMID   34978615. S2CID   245636454.
137. Tang P, Zhang J, Peng S, Wang Y, Li H, Wang Z, et al. (2023). "Genotype-phenotype correlation in patients with 21-hydroxylase deficiency". Frontiers in Endocrinology. 14: 1095719. doi: 10.3389/fendo.2023.1095719 . PMC   10042299 . PMID   36992809.
138. Kim JH, Kim GH, Yoo HW, Choi JH (June 2023). "Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome". Annals of Pediatric Endocrinology & Metabolism. 28 (2): 77–86. doi:10.6065/apem.2346108.054. PMC   10329939 . PMID   37401054.
139. Polat S, Arslan YK (March 2022). "17-Hydroxyprogesterone Response to Standard Dose Synacthen Stimulation Test in CYP21A2 Heterozygous Carriers and Non-carriers in Symptomatic and Asymptomatic Groups: Meta-analyses". Journal of Clinical Research in Pediatric Endocrinology. 14 (1): 56–68. doi:10.4274/jcrpe.galenos.2021.2021.0184. PMC   8900072 . PMID   34743977.
140. Concolino P (October 2019). "Issues with the Detection of Large Genomic Rearrangements in Molecular Diagnosis of 21-Hydroxylase Deficiency". Molecular Diagnosis & Therapy. 23 (5): 563–567. doi:10.1007/s40291-019-00415-z. PMID   31317337. S2CID   197543506.
141. Cheng T, Liu J, Sun W, Song G, Ma H (March 2022). "Congenital adrenal hyperplasia with homozygous and heterozygous mutations: a rare family case report". BMC Endocrine Disorders. 22 (1): 57. doi: 10.1186/s12902-022-00969-w . PMC   8900299 . PMID   35255871.
142. Dörr HG, Schulze N, Bettendorf M, Binder G, Bonfig W, Denzer C, et al. (July 2020). "Genotype-phenotype correlations in children and adolescents with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Molecular and Cellular Pediatrics. 7 (1): 8. doi: 10.1186/s40348-020-00100-w . PMC   7347723 . PMID   32647925.
143. Pignatelli D, Carvalho BL, Palmeiro A, Barros A, Guerreiro SG, Macut D (2019). "The Complexities in Genotyping of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency". Frontiers in Endocrinology. 10: 432. doi: 10.3389/fendo.2019.00432 . PMC   6620563 . PMID   31333583.
144. Tusie-Luna MT, Traktman P, White PC (December 1990). "Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus". The Journal of Biological Chemistry. 265 (34): 20916–20922. doi: 10.1016/S0021-9258(17)45304-X . PMID   2249999.
145. Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimur F, Moran C, Oberfield S, et al. (September 2017). "Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women". Human Reproduction Update. 23 (5): 580–599. doi: 10.1093/humupd/dmx014 . PMID   28582566.
146. Neocleous V, Shammas C, Phedonos AP, Karaoli E, Kyriakou A, Toumba M, et al. (September 2012). "Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia". Georgian Medical News (210): 40–47. PMID   23045419.
147. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y (June 2006). "Hyperandrogenism in carriers of CYP21 mutations: the role of genotype". Clinical Endocrinology. 64 (6): 645–651. doi:10.1111/j.1365-2265.2006.02521.x. PMID   16712666. S2CID   37571628.
148. Félix-López X, Riba L, Ordóñez-Sánchez ML, Ramírez-Jiménez S, Ventura-Gallegos JL, Zentella-Dehesa A, Tusié-Luna MT (September 2003). "Steroid 21-hydroxylase (P450c21) naturally occurring mutants I172N, V281L and I236n/V237E/M239K exert a dominant negative effect on enzymatic activity when co-expressed with the wild-type protein". Journal of Pediatric Endocrinology & Metabolism. 16 (7): 1017–1024. doi:10.1515/jpem.2003.16.7.1017. PMID   14513879. S2CID   40680772.
149. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y (May 1986). "Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene". Proceedings of the National Academy of Sciences of the United States of America. 83 (9): 2841–2845. Bibcode:1986PNAS...83.2841H. doi: 10.1073/pnas.83.9.2841 . PMC   323402 . PMID   3486422.
150. Concolino P, Rizza R, Costella A, Carrozza C, Zuppi C, Capoluongo E (June 2017). "CYP21A2 intronic variants causing 21-hydroxylase deficiency". Metabolism. 71: 46–51. doi:10.1016/j.metabol.2017.03.003. PMID   28521877.
151. Miller WL, Merke DP (2018). "Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome". Hormone Research in Paediatrics. 89 (5): 352–361. doi:10.1159/000481911. PMC   6057477 . PMID   29734195.
152. Yu CY (1999). "Molecular genetics of the human MHC complement gene cluster". Experimental and Clinical Immunogenetics. 15 (4): 213–230. doi:10.1159/000019075. PMID   10072631. S2CID   25061446.
153. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL (February 1985). "Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man". Proceedings of the National Academy of Sciences of the United States of America. 82 (4): 1089–1093. Bibcode:1985PNAS...82.1089W. doi: 10.1073/pnas.82.4.1089 . PMC   397199 . PMID   2983330.
154. Xie T, Rowen L, Aguado B, Ahearn ME, Madan A, Qin S, et al. (December 2003). "Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse". Genome Research. 13 (12): 2621–2636. doi:10.1101/gr.1736803. PMC   403804 . PMID   14656967.
155. Bánlaki Z, Doleschall M, Rajczy K, Fust G, Szilágyi A (October 2012). "Fine-tuned characterization of RCCX copy number variants and their relationship with extended MHC haplotypes". Genes and Immunity. 13 (7): 530–535. doi: 10.1038/gene.2012.29 . PMID   22785613. S2CID   36582994.
156. Carrozza C, Foca L, De Paolis E, Concolino P (2021). "Genes and Pseudogenes: Complexity of the RCCX Locus and Disease". Frontiers in Endocrinology. 12: 709758. doi: 10.3389/fendo.2021.709758 . PMC   8362596 . PMID   34394006.
157. Sweeten TL, Odell DW, Odell JD, Torres AR (January 2008). "C4B null alleles are not associated with genetic polymorphisms in the adjacent gene CYP21A2 in autism". BMC Medical Genetics. 9: 1. doi: 10.1186/1471-2350-9-1 . PMC   2265260 . PMID   18179706.
158. Milner CM, Campbell RD (August 2001). "Genetic organization of the human MHC class III region". Frontiers in Bioscience. 6: D914–D926. doi: 10.2741/milner . PMID   11487476.
159. Bánlaki Z, Szabó JA, Szilágyi Á, Patócs A, Prohászka Z, Füst G, Doleschall M (2013). "Intraspecific evolution of human RCCX copy number variation traced by haplotypes of the CYP21A2 gene". Genome Biol Evol. 5 (1): 98–112. doi:10.1093/gbe/evs121. PMC   3595039 . PMID   23241443.
160. Tsai LP, Lee HH (September 2012). "Analysis of CYP21A1P and the duplicated CYP21A2 genes". Gene. 506 (1): 261–262. doi:10.1016/j.gene.2012.06.045. PMID   22771554.
161. Adachi E, Nakagawa R, Tsuji-Hosokawa A, Gau M, Kirino S, Yogi A, Nakatani H, Takasawa K, Yamaguchi T, Kosho T, Murakami M, Tajima T, Hasegawa T, Yamada T, Morio T, Ohara O, Kashimada K (October 2023). "A MinION-Based Long-Read Sequencing Application with One-Step PCR for the Genetic Diagnosis of 21-Hydroxylase Deficiency". J Clin Endocrinol Metab. 109 (3): 750–760. doi: 10.1210/clinem/dgad577 . PMID   37804107. S2CID   263742489.
162. "CYP21A2 gene: MedlinePlus Genetics". medlineplus.gov. Retrieved 2023-11-15.
163. Castro SM, Wiest P, Spritzer PM, Kopacek C (December 2023). "The impact of neonatal 17-hydroxyprogesterone cutoff determination in a public newborn screening program for congenital adrenal hyperplasia in Southern Brazil: 3 years' experience". Endocrine Connections. 12 (12). doi:10.1530/EC-23-0162. PMC   10620452 . PMID   37902057. S2CID   263150618.
164. S L, Krishna Prasad H, Ramjee B, Venugopalan L, Ganapathy N, Paramasamy B (2023). "Audit of management of children and adolescents with congenital adrenal hyperplasia as per recent Endocrine Society guidelines". Pediatric Endocrinology, Diabetes, and Metabolism. 29 (1): 10–15. doi:10.5114/pedm.2022.122547. PMC   10226460 . PMID   36734395.
165. Deaton MA, Glorioso JE, McLean DB (March 1999). "Congenital adrenal hyperplasia: not really a zebra". Am Fam Physician. 59 (5): 1190–6, 1172. PMID   10088875.
166. Forest MG, Tardy V, Nicolino M, David M, Morel Y (June 2005). "21-Hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease". Annales d'Endocrinologie. 66 (3): 225–232. doi:10.1016/s0003-4266(05)81754-8. PMID   15988383.
167. Yoon YA, Woo S, Kim MS, Kim B, Choi YJ (April 2023). "Establishing 17-Hydroxyprogesterone Cutoff Values for Congenital Adrenal Hyperplasia in Preterm, Low Birth Weight, and Sick Newborns". Experimental and Clinical Endocrinology & Diabetes. 131 (4): 216–221. doi:10.1055/a-2022-8399. PMID   36854385. S2CID   257255642.
168. Kwon C, Farrell PM (July 2000). "The magnitude and challenge of false-positive newborn screening test results". Archives of Pediatrics & Adolescent Medicine. 154 (7): 714–718. doi:10.1001/archpedi.154.7.714. PMID   10891024.
169. Therrell BL (March 2001). "Newborn screening for congenital adrenal hyperplasia". Endocrinology and Metabolism Clinics of North America. 30 (1): 15–30. doi:10.1016/s0889-8529(08)70017-3. PMID   11344933.
170. Kotwal N, Lekarev O (2022). "Pitfalls of prenatal and newborn screening in congenital adrenal hyperplasia: A narrative review". Pediatric Medicine. 6: 34. doi: 10.21037/pm-21-104 .
171. de Hora MR, Heather NL, Patel T, Bresnahan LG, Webster D, Hofman PL (March 2020). "Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand". International Journal of Neonatal Screening. 6 (1): 6. doi: 10.3390/ijns6010006 . PMC   7422986 . PMID   33073005.
172. Bialk ER, Lasarev MR, Held PK (September 2019). "Wisconsin's Screening Algorithm for the Identification of Newborns with Congenital Adrenal Hyperplasia". International Journal of Neonatal Screening. 5 (3): 33. doi: 10.3390/ijns5030033 . PMC   7510207 . PMID   33072992.
173. Gau M, Konishi K, Takasawa K, Nakagawa R, Tsuji-Hosokawa A, Hashimoto A, et al. (February 2021). "The progression of salt-wasting and the body weight change during the first 2 weeks of life in classical 21-hydroxylase deficiency patients". Clinical Endocrinology. 94 (2): 229–236. doi:10.1111/cen.14347. PMID   33001476. S2CID   222165169.
174. Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. (August 2009). "Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience". Pediatric Research. 66 (2): 230–235. doi: 10.1203/PDR.0b013e3181aa3777 . PMID   19390483.
175. Sarafoglou K, Merke DP, Reisch N, Claahsen-van der Grinten H, Falhammar H, Auchus RJ (August 2023). "Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management". J Clin Endocrinol Metab. 108 (9): 2154–2175. doi:10.1210/clinem/dgad134. PMC   10438890 . PMID   36950738.
176. Bacila IA, Lawrence NR, Badrinath SG, Balagamage C, Krone NP (August 2023). "Biomarkers in congenital adrenal hyperplasia". Clin Endocrinol (Oxf). doi: 10.1111/cen.14960 . PMID   37608608.
177. Greaves RF, Kumar M, Mawad N, Francescon A, Le C, O'Connell M, et al. (October 2023). "Best Practice for Identification of Classical 21-Hydroxylase Deficiency Should Include 21 Deoxycortisol Analysis with Appropriate Isomeric Steroid Separation". International Journal of Neonatal Screening. 9 (4): 58. doi: 10.3390/ijns9040058 . PMC   10594498 . PMID   37873849.
178. Cristoni S, Cuccato D, Sciannamblo M, Bernardi LR, Biunno I, Gerthoux P, et al. (2004). "Analysis of 21-deoxycortisol, a marker of congenital adrenal hyperplasia, in blood by atmospheric pressure chemical ionization and electrospray ionization using multiple reaction monitoring". Rapid Communications in Mass Spectrometry. 18 (1): 77–82. Bibcode:2004RCMS...18...77C. doi:10.1002/rcm.1284. PMID   14689562.
179. Miller WL (2019). "Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol". Hormone Research in Paediatrics. 91 (6): 416–420. doi: 10.1159/000501396 . PMID   31450227. S2CID   201733086.
180. Held PK, Bialk ER, Lasarev MR, Allen DB (March 2022). "21-Deoxycortisol is a Key Screening Marker for 21-Hydroxylase Deficiency". The Journal of Pediatrics. 242: 213–219.e1. doi:10.1016/j.jpeds.2021.10.063. PMID   34780778. S2CID   244106268.
181. Gueux B, Fiet J, Galons H, Boneté R, Villette JM, Vexiau P, et al. (January 1987). "The measurement of 11 beta-hydroxy-4-pregnene-3,20-dione (21-deoxycorticosterone) by radioimmunoassay in human plasma". Journal of Steroid Biochemistry. 26 (1): 145–150. doi:10.1016/0022-4731(87)90043-4. PMID   3546944.
182. Fiet J, Gueux B, Raux-DeMay MC, Kuttenn F, Vexiau P, Brerault JL, et al. (March 1989). "Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway". The Journal of Clinical Endocrinology and Metabolism. 68 (3): 542–547. doi:10.1210/jcem-68-3-542. PMID   2537337.
183. Sarathi V, Atluri S, Pradeep TV, Rallapalli SS, Rakesh CV, Sunanda T, Kumar KD (2019). "Utility of a Commercially Available Blood Steroid Profile in Endocrine Practice". Indian Journal of Endocrinology and Metabolism. 23 (1): 97–101. doi: 10.4103/ijem.IJEM_531_18 . PMC   6446682 . PMID   31016162.
184. Dimitrakov, Jordan; Joffe, Hylton V.; Soldin, Steven J.; Bolus, Roger; Buffington, C.A. Tony; Nickel, J. Curtis (2008). "Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome". Urology. 71 (2): 261–6. doi:10.1016/j.urology.2007.09.025. PMC   2390769 . PMID   18308097.
185. Masiutin, Maxim G.; Yadav, Maneesh K. (2022). "Letter to the editor regarding the article "Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome"". Urology. 169: 273. doi:10.1016/j.urology.2022.07.051. ISSN   0090-4295. PMID   35987379. S2CID   251657694.
186. Dimitrakoff, Jordan; Nickel, J. Curtis (2022). "AUTHOR REPLY". Urology. 169: 273–274. doi:10.1016/j.urology.2022.07.049. ISSN   0090-4295. PMID   35985522. S2CID   251658492.
187. Winter WE, Bazydlo L, Harris NS (2012). "Cortisol – Clinical Indications and Laboratory Testing". AACC Clinical Laboratory News.
188. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S (2014). "Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction". BMC Clinical Pathology. 14 (33): 33. doi: 10.1186/1472-6890-14-33 . PMC   4112981 . PMID   25071417.
189. Hawley JM, Keevil BG (September 2016). "Endogenous glucocorticoid analysis by liquid chromatography-tandem mass spectrometry in routine clinical laboratories". The Journal of Steroid Biochemistry and Molecular Biology. 162: 27–40. doi:10.1016/j.jsbmb.2016.05.014. PMID   27208627. S2CID   206501499.
190. Kurtoğlu S, Hatipoğlu N (March 2017). "Non-Classical Congenital Adrenal Hyperplasia in Childhood". Journal of Clinical Research in Pediatric Endocrinology. 9 (1): 1–7. doi:10.4274/jcrpe.3378. PMC   5363159 . PMID   27354284.
191. D'aurizio F, Cantù M (September 2018). "Clinical endocrinology and hormones quantitation: the increasing role of mass spectrometry". Minerva Endocrinologica. 43 (3): 261–284. doi:10.23736/S0391-1977.17.02764-X. PMID   29083134. S2CID   12984040.
192. Maher JY, Gomez-Lobo V, Merke DP (February 2023). "The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum". Reviews in Endocrine & Metabolic Disorders. 24 (1): 71–83. doi:10.1007/s11154-022-09770-5. PMC   9884653 . PMID   36399318.
193. Nimkarn S, New MI (March 2010). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A paradigm for prenatal diagnosis and treatment". Annals of the New York Academy of Sciences. 1192: 5–11. doi:10.1111/j.1749-6632.2009.05225.x. PMID   20392211. S2CID   38359933.
194. Khattab A, Yuen T, Sun L, Yau M, Barhan A, Zaidi M, Lo YM, New MI (2016). "Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia". Advanced Therapies in Pediatric Endocrinology and Diabetology. Endocrine Development. Vol. 30. S.Karger AG. pp. 37–41. doi:10.1159/000439326. ISBN   978-3-318-05636-5. PMID   26683339.
195. Hutson JM, Warne GL, Grover SL, eds. (2012). Disorders of Sex Development. Springer Berlin, Heidelberg. doi:10.1007/978-3-642-22964-0. ISBN   978-3-642-22964-0.
196. Miller WL, Witchel SF (May 2013). "Prenatal treatment of congenital adrenal hyperplasia: risks outweigh benefits". American Journal of Obstetrics and Gynecology. 208 (5): 354–359. doi:10.1016/j.ajog.2012.10.885. PMID   23123167.
197. Miller WL (June 2015). "Fetal endocrine therapy for congenital adrenal hyperplasia should not be done". Best Practice & Research. Clinical Endocrinology & Metabolism. 29 (3): 469–483. doi:10.1016/j.beem.2015.01.005. PMID   26051303.
198. Cera G, Locantore P, Novizio R, Maggio E, Ramunno V, Corsello A, et al. (October 2022). "Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia". Journal of Clinical Medicine. 11 (20): 6156. doi: 10.3390/jcm11206156 . PMC   9605322 . PMID   36294476.
199. Levine LS, Pang S (1994). "Prenatal diagnosis and treatment of congenital adrenal hyperplasia". The Journal of Pediatric Endocrinology. 7 (3): 193–200. doi:10.1515/jpem.1994.7.3.193. PMID   7820212. S2CID   37158917.
200. Heland S, Hewitt JK, McGillivray G, Walker SP (June 2016). "Preventing female virilisation in congenital adrenal hyperplasia: The controversial role of antenatal dexamethasone". The Australian & New Zealand Journal of Obstetrics & Gynaecology. 56 (3): 225–232. doi: 10.1111/ajo.12423 . PMID   26661642. S2CID   25816572.
201. Van't Westeinde A, Karlsson L, Messina V, Wallensteen L, Brösamle M, Dal Maso G, et al. (April 2023). "An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia". Endocrine Connections. 12 (4). doi:10.1530/EC-22-0400. PMC   10083667 . PMID   36752813.
202. Meyer-Bahlburg HF, Dolezal C, Haggerty R, Silverman M, New MI (July 2012). "Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency". European Journal of Endocrinology. 167 (1): 103–110. doi:10.1530/EJE-11-0789. PMC   3383400 . PMID   22549088.
203. Elton C (2010-06-18). "A Prenatal Treatment Raises Questions of Medical Ethics". Time .
204. Hirvikoski T, Nordenström A, Wedell A, Ritzén M, Lajic S (June 2012). "Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint". The Journal of Clinical Endocrinology and Metabolism. 97 (6): 1881–1883. doi: 10.1210/jc.2012-1222 . PMID   22466333.
205. Dreger A, Feder EK, Tamar-Mattis A (2010-06-29). "Preventing Homosexuality (and Uppity Women) in the Womb?". Bioethics Forum, a service of the Hastings Center. Retrieved 2010-07-05.
206. Dreger A, Feder EK, Tamar-Mattis A (September 2012). "Prenatal Dexamethasone for Congenital Adrenal Hyperplasia: An Ethics Canary in the Modern Medical Mine". Journal of Bioethical Inquiry. 9 (3): 277–294. doi:10.1007/s11673-012-9384-9. PMC   3416978 . PMID   22904609.
207. Meyer-Bahlburg H (1990). "Will Prenatal Hormone Treatment Prevent Homosexuality?". Journal of Child and Adolescent Psychopharmacology. 1 (4): 279–283. doi:10.1089/cap.1990.1.279.
208. Mercè Fernández-Balsells M, Muthusamy K, Smushkin G, Lampropulos JF, Elamin MB, Abu Elnour NO, et al. (October 2010). "Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses". Clinical Endocrinology. 73 (4): 436–444. doi: 10.1111/j.1365-2265.2010.03826.x . PMID   20550539. S2CID   29694687.
209. Whittle E, Falhammar H (June 2019). "Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis". J Endocr Soc. 3 (6): 1227–1245. doi:10.1210/js.2019-00136. PMC   6546346 . PMID   31187081.
210. Ng SM, Stepien KM, Krishan A (March 2020). "Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia". Cochrane Database Syst Rev. 2020 (3): CD012517. doi:10.1002/14651858.CD012517.pub2. PMC   7081382 . PMID   32190901.
211. Adriaansen BP, Kamphuis JS, Schröder MA, Olthaar AJ, Bock C, Brandt A, et al. (July 2022). "Diurnal salivary androstenedione and 17-hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia". Clinical Endocrinology. 97 (1): 36–42. doi:10.1111/cen.14690. PMC   9542109 . PMID   35150157.
212. Nordenström A, Lajic S, Falhammar H (June 2021). "Clinical outcomes in 21-hydroxylase deficiency". Current Opinion in Endocrinology, Diabetes, and Obesity. 28 (3): 318–324. doi:10.1097/MED.0000000000000625. PMID   33741777. S2CID   232298877.
213. White PC (June 2022). "Emerging treatment for congenital adrenal hyperplasia". Current Opinion in Endocrinology, Diabetes, and Obesity. 29 (3): 271–276. doi:10.1097/MED.0000000000000723. PMC   9302862 . PMID   35283460.
214. Bonfig W, Schwarz HP (December 2014). "Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age". Clin Endocrinol (Oxf). 81 (6): 871–5. doi: 10.1111/cen.12498 . PMID   24818525.
215. Falhammar H, Frisén L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjöld A, Nordenström A (December 2014). "Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency". J Clin Endocrinol Metab. 99 (12): E2715–21. doi: 10.1210/jc.2014-2957 . hdl: 10616/45611 . PMID   25279502. S2CID   3159398.
216. Worth C, Vyas A, Banerjee I, Lin W, Jones J, Stokes H, Komlosy N, Ball S, Clayton P (2021). "Acute Illness and Death in Children With Adrenal Insufficiency". Front Endocrinol (Lausanne). 12: 757566. doi: 10.3389/fendo.2021.757566 . PMC   8548653 . PMID   34721304.
217. "Medical Conditions: Adrenal Insufficiency". MedicAlert Foundation. 2022-08-10. Retrieved 2023-11-15.
218. Dabas A, Vats P, Sharma R, Singh P, Seth A, Jain V, Batra P, Gupta N, Kumar R, Kabra M, Kapoor S, Yadav S (February 2020). "Management of Infants with Congenital Adrenal Hyperplasia". Indian Pediatr. 57 (2): 159–164. doi:10.1007/s13312-020-1735-8. PMID   32060243. S2CID   211122771.
219. Almasri J, Zaiem F, Rodriguez-Gutierrez R, Tamhane SU, Iqbal AM, Prokop LJ, Speiser PW, Baskin LS, Bancos I, Murad MH (November 2018). "Genital Reconstructive Surgery in Females With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis". J Clin Endocrinol Metab. 103 (11): 4089–4096. doi: 10.1210/jc.2018-01863 . PMID   30272250. S2CID   52890676.
220. "Clitoridectomy and Female Circumcision in America".
221. Nordenström A, Falhammar H, Lajic S (January 2022). "Current and novel treatment strategies in children with congenital adrenal hyperplasia". Hormone Research in Paediatrics. 96 (6): 560–572. doi: 10.1159/000522260 . PMID   35086098. S2CID   246360028.
222. Apsan J, Thomas C, Elnaas H, Lin-Su K, Lekarev O (2022). "Twice Daily Compared to Three Times Daily Hydrocortisone in Prepubertal Children with Congenital Adrenal Hyperplasia". Hormone Research in Paediatrics. 95 (1): 62–67. doi: 10.1159/000523808 . PMID   35220302. S2CID   247131531.
223. Sarafoglou K, Addo OY, Hodges JS, Brundage RC, Lightman SL, Hindmarsh PC, Miller BS (2022). "The Evidence for Twice-Daily Hydrocortisone Dosing in Children with Congenital Adrenal Hyperplasia Is Lacking". Hormone Research in Paediatrics. 95 (5): 499–504. doi: 10.1159/000525990 . PMID   35817014. S2CID   250453213.
224. Schagen SE, Cohen-Kettenis PT, Delemarre-van de Waal HA, Hannema SE (July 2016). "Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents". J Sex Med. 13 (7): 1125–32. doi:10.1016/j.jsxm.2016.05.004. PMID   27318023.
225. "Premature Adrenarche - Pediatric Endocrine Society". 17 June 2020.
226. "Precocious Puberty (Early Puberty)". 23 August 2014.
227. Migeon CJ, Wisniewski AB (March 2001). "Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations". Endocrinology and Metabolism Clinics of North America. 30 (1): 193–206. doi:10.1016/S0889-8529(08)70026-4. PMID   11344936.
228. Daae E, Feragen KB, Waehre A, Nermoen I, Falhammar H (2020). "Sexual Orientation in Individuals With Congenital Adrenal Hyperplasia: A Systematic Review". Frontiers in Behavioral Neuroscience. 14: 38. doi: 10.3389/fnbeh.2020.00038 . PMC   7082355 . PMID   32231525.
229. Szymanski KM, Rink RC, Whittam B, Hensel DJ (April 2021). "Majority of females with a life-long experience of CAH and parents do not consider females with CAH to be intersex". Journal of Pediatric Urology. 17 (2): 210.e1–210.e9. doi:10.1016/j.jpurol.2020.09.009. hdl: 1805/27714 . PMID   33041207. S2CID   222300981.
230. Falhammar H, Hirschberg AL, Nordenskjöld A, Larsson H, Nordenström A (October 2023). "Increased Prevalence of Accidents and Injuries in Congenital Adrenal Hyperplasia: A Population-Based Cohort Study". J Clin Endocrinol Metab. 109 (3): e1175–e1184. doi: 10.1210/clinem/dgad624 . PMC   10876393 . PMID   37862468.
231. Harasymiw LA, Grosse SD, Cullen KR, Bitsko RH, Perou R, Sarafoglou K (2023). "Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States". Front Endocrinol (Lausanne). 14: 1129584. doi: 10.3389/fendo.2023.1129584 . PMC   10470620 . PMID   37664854.
232. Hamed SA, Attiah FA, Abd Elaal RF, Fawzy M (March 2021). "Behavioral assessment of females with congenital adrenal hyperplasia". Hormones (Athens). 20 (1): 131–141. doi:10.1007/s42000-020-00232-8. PMID   32740726. S2CID   220907439.
233. Gao Y, Lu L, Yu B, Mao J, Wang X, Nie M, Wu X (July 2020). "The Prevalence of the Chimeric TNXA/TNXB Gene and Clinical Symptoms of Ehlers-Danlos Syndrome with 21-Hydroxylase Deficiency". J Clin Endocrinol Metab. 105 (7): 2288–2299. doi: 10.1210/clinem/dgaa199 . PMID   32291442.
234. Concolino P, Falhammar H (May 2022). "CAH-X Syndrome: Genetic and Clinical Profile". Mol Diagn Ther. 26 (3): 293–300. doi:10.1007/s40291-022-00588-0. PMID   35476220. S2CID   248402892.
235. Hannah-Shmouni F, Morissette R, Sinaii N, Elman M, Prezant TR, Chen W, et al. (November 2017). "Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians". Genetics in Medicine. 19 (11): 1276–1279. doi:10.1038/gim.2017.46. PMC   5675788 . PMID   28541281. S2CID   4630175.
236. Miller WL, White PC (2022). "A Brief History of Congenital Adrenal Hyperplasia". Hormone Research in Paediatrics. 95 (6): 529–545. doi: 10.1159/000526468 . PMID   36446323. S2CID   254095026.
237. Delle Piane L, Rinaudo PF, Miller WL (April 2015). "150 years of congenital adrenal hyperplasia: translation and commentary of De Crecchio's classic paper from 1865". Endocrinology. 156 (4): 1210–1217. doi: 10.1210/en.2014-1879 . PMID   25635623. S2CID   36312972.
238. Carroll L, Graff C, Wicks M, Diaz Thomas A (March 2020). "Living with an invisible illness: a qualitative study exploring the lived experiences of female children with congenital adrenal hyperplasia". Qual Life Res. 29 (3): 673–681. doi:10.1007/s11136-019-02350-2. PMID   31823183. S2CID   208957761.
239. Liamputtong, Pranee; Rice, Zoe Sanipreeya (2021), Liamputtong, Pranee (ed.), "Stigma, Discrimination, and Social Exclusion", Handbook of Social Inclusion, Cham: Springer International Publishing, pp. 1–17, doi:10.1007/978-3-030-48277-0_6-2, ISBN   978-3-030-48277-0 , retrieved 2023-11-15
240. Fausto-Sterling A (30 November 2000). Sexing the body : gender politics and the construction of sexuality. [New York]: Basic Books. ISBN   9780465077137.
241. "Intersex babies are perfect just as they are!". UN Free & Equal. up to 1.7 percent of babies are born with sex characteristics that don't fit typical definitions of male and female. That makes being intersex almost as common as being a redhead!
242. "Its Intersex Awareness Day - here are 5 myths we need to shatter". www.amnesty.org. 26 October 2018. According to experts, around 1.7% of the population is born with intersex traits - comparable to the number of people born with red hair.
243. "What is Intersex? Frequently Asked Questions". interACT: Advocates for Intersex Youth. About 1.7% of people are born intersex. (Compare that to a ~0.3% chance of having identical twins!) 1 in 2,000 babies (0.05% of humans) are born with genital differences that a doctor might suggest changing with unnecessary surgery.
244. "Intersex population figures". Intersex Human Rights Australia. 28 September 2013. Given that intersex people only come to the attention of data collectors through chance or an apparent medical reason, the actual numbers of people with intersex variations are likely to be as much as 1.7%. Despite the limitations of the data, 1.7% seems more justifiable as an upper limit figure than alternatives, to date.
245. Sax L (August 2002). "How common is intersex? a response to Anne Fausto-Sterling". Journal of Sex Research . 39 (3): 174–8. doi:10.1080/00224490209552139. PMID   12476264. S2CID   33795209. Reviewing the list of conditions which Fausto-Sterling considers to be intersex, we find that this one condition–late-onset congenital adrenal hyperplasia (LOCAH)–accounts for 88% of all those patients whom Fausto-Sterling classifies as intersex (1.5/1.7 = 88%). From a clinician's perspective, however, LOCAH is not an intersex condition. The genitalia of these babies are normal at birth, and consonant with their chromosomes: XY males have normal male genitalia, and XX females have normal female genitalia.
246. Best J (14 September 2013). Stat-spotting : a field guide to identifying dubious data (Updated and expand ed.). Berkeley: University of California Press. pp. 12–13. ISBN   978-0520279988.
247. Gondim R, Teles F, Barroso U (December 2018). "Sexual orientation of 46, XX patients with congenital adrenal hyperplasia: a descriptive review". Journal of Pediatric Urology. 14 (6): 486–493. doi:10.1016/j.jpurol.2018.08.004. PMID   30322770. S2CID   53507149.
248. Meyer-Bahlburg HF (March 2001). "Gender and sexuality in classic congenital adrenal hyperplasia". Endocrinology and Metabolism Clinics of North America. 30 (1): 155–71, viii. doi:10.1016/s0889-8529(08)70024-0. PMID   11344934.
249. Zainuddin AA, Grover SR, Shamsuddin K, Mahdy ZA (December 2013). "Research on quality of life in female patients with congenital adrenal hyperplasia and issues in developing nations". Journal of Pediatric and Adolescent Gynecology. 26 (6): 296–304. doi:10.1016/j.jpag.2012.08.004. PMID   23507003.
250. Finkielstain GP, Rey RA (2023). "Challenges in managing disorders of sex development associated with adrenal dysfunction". Expert Review of Endocrinology & Metabolism. 18 (5): 427–439. doi:10.1080/17446651.2023.2256393. PMID   37694439. S2CID   261575934.
251. PhD, Hida Viloria and Professor Maria Nieto. "Intersex Activist Hida Viloria and Maria Nieto PhD announce 'The Spectrum of Sex' Book". www.prweb.com. Retrieved 2023-11-15.
252. "These are the 10 best memoirs and autobiographies to read now". Harper's BAZAAR. 2023-07-06. Retrieved 2023-11-15.
253. Tang R, Xu Z (November 2020). "Gene therapy: a double-edged sword with great powers". Molecular and Cellular Biochemistry. 474 (1–2): 73–81. doi:10.1007/s11010-020-03834-3. PMID   32696132. S2CID   220656773.
254. Glazova O, Bastrich A, Deviatkin A, Onyanov N, Kaziakhmedova S, Shevkova L, et al. (March 2023). "Models of Congenital Adrenal Hyperplasia for Gene Therapies Testing". International Journal of Molecular Sciences. 24 (6): 5365. doi: 10.3390/ijms24065365 . PMC   10049562 . PMID   36982440.

External links

• GeneReviews/NCBI/NIH/UW entry on 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia
• OMIM entry on 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia